

PUBLICATIONS

Refereed Articles:

1. Trautner EM, Trethewie ER, Gershon S. The analeptic effect of succinate in coma and in confusional states. *Med J Aust*, 2:848-865, 1953.
2. Trautner EM, Gershon S, Duerrheim, GE. Treatment of schizophrenia by combined barbiturate-succinate therapy. *Med J Aust*, 2:181-188, 1954.
3. Gershon S, Trautner EM. The treatment of depressive psychosis with sodium succinate. *Med J Aust*, 2:291-298, 1954.
4. Trautner EM, Morris R, Noack CH, Gershon S. The excretion and retention of ingested lithium and its effect on the ionic balance of man. *Med J Aust*, 2:280-291, 1955.
5. Trautner EM, Shaw FH, Gershon S. Bemegride in barbiturate poisoning. *Lancet*, 2:1214, 1956.
6. Trethewie ER, Trautner EM, Gershon S. The effects of succinate on the number of circulating eosinophils in man and in the cat. *Aust J Exp Biol Med Sci*, 34:109-120, 1956.
7. Gershon S, Trautner EM. The treatment of shock-dependency by pharmacological agents. *Med J Aust*, 1:783-787, 1956.
8. Gershon S, Shaw FH, Trautner EM. Treatment of barbiturate poisoning. *Br Med J*, 1:231, 1957.
9. Coats DA, Trautner EM, Gershon S. Treatment of lithium poisoning. *Aust Ann Med*, 1(6):11-15, 1957.
10. Shaw FH, Gershon S, Bentley GA. Morphine antagonism. *J Pharm*, 9:666-671, 1957.
11. Gershon S, Shaw FH. Effects of bemegride on barbiturate overdosage in humans. *Br Med J*, 2:1509-1514, 1957.
12. Trautner EM, Pennycuik PR, Morris RJH, Gershon S, Shankly KH. The effects of prolonged sub-toxic lithium ingestion on pregnancy in rats. *Aust J Exp Biol Med Sci*, 36:305-321, 1958.
13. Christie G, Shaw FH, McCance I, Bruce DW, Gershon S. Treatment of certain side effects of morphine. *Br Med J*, 1:675-680, 1958.
14. Gershon S, Bruce DW, Orchard N, Shaw FH. Amiphenazole and morphine in production of analgesia. *Br Med J*, 2:366-368, 1958.
15. Gershon S, Shaw FH. Morphine and histamine release. *J Pharm*, 10:22-29, 1958.
16. Gershon S, Shaw FH. Tetrahydroaminacrin as a decurarising agent. *J Pharm*, 10:638-641, 1958.
17. Gershon S, Shaw FH. Propionyl atropine methyl nitrate in the symptomatic treatment of peptic ulcer. *Med J Aust*, 2:605-606, 1958.
18. Trautner EM, Gershon S. The effect of tigloidine on extrapyramidal syndromes (Huntington's chorea). *Aust Ann Med*, 7(4):268-291, 1958.

19. Troy CA, Gershon S, Morgan PJ. A case of meprobamate coma with convulsions. *Med J Aust*, 2:667-668, 1958.
20. Trautner EM, Gershon S. Use of tremorine for screening anti-Parkinsonian drugs. *Nature*, 183:1462-1463, 1959.
21. O'Rourke FJ, Gershon S, Trautner EM, Shaw FH. The use of tigloidine in the symptomatic treatment of spastic paraplegia. *Med J Aust*, 1:73-77, 1960.
22. Gershon S, Yuwiler A. Lithium ion: A specific psychopharmacological approach to the treatment of mania. *J Neuropsychiat*, 1:229-241, 1960.
23. Gershon S. Blocking effect of tetrahydroaminacrin on a new psychotomimetic agent. *Nature*, 186:1072-1073, 1960.
24. Gershon S, Olariu J. JB-329 - A new psychomimetic - its antagonism by tetrahydroaminacrin and its comparison with LSD, mescaline and sernyl. *J Neuropsychiat*, 1:283-292, 1960.
25. Holmberg G, Gershon S. Autonomic and psychic effects of yohimbine hydrochloride. *Psychopharmacology*, 2:93-106, 1961.
26. Gershon S, Shaw FH. Psychiatric sequelae of chronic exposure to organophosphorus insecticides. *Lancet*, 1:1371-1374, 1961.
27. Gershon S, Trethewie ER, Crawford M. The use of succinic acid in the treatment of acute carbon monoxide poisoning. *Arch Int Pharmacodyn*, 134:16-27, 1961.
28. Gershon S, Lang WJ. A psychopharmacological study of some indole alkaloids. *Arch Int Pharmacodyn*, 135:31-56, 1961.
29. Cairncross KD, Gershon S. A pharmacological basis for the cardiovascular complications of imipramine medication. *Med J Aust*, 49(2):372-375, 1962.
30. Jotkowitz JW, Gershon S. Manic reactions following combined Tofranil (imipramine) and E.C.T. *Med J Aust*, 1:87-90, 1961.
31. Rosenbaum M, Gershon S. Experiences with a new antidepressant amitriptyline. *Med J Aust*, 49(1):321-324, 1962.
32. Gershon S, Holmberg G, Mattsson E, Mattsson N, Marshall A. Imipramine hydrochloride, its effects on clinical, autonomic and physiological functions. *Arch Gen Psychiat*, 6:96-101, 1962.
33. Holmberg G, Gershon S, Beck L. Yohimbine as an autonomic test drug. *Nature*, 193:1313-1314, 1962.
34. Lang W, Gershon S. Effects of psychoactive drugs on Yohimbine-induced responses in conscious dogs - A study of antidepressant drugs. *Med Exp*, 7:125-134, 1962.
35. Cairncross KD, Gershon S, Gust ID. Some aspects of the mode of action of imipramine. *J Neuropsychiat*, 4:224-231, 1963.
36. Lang WJ, Gershon S. Effects of psychoactive drugs on Yohimbine-induced responses in conscious dogs - A proposed screening procedure for anti-anxiety agents. *Arch Int Pharmacodyn*, 142:457-472, 1963.
37. Gershon S, Bell C. A study of the antagonism of some indole-alkaloids to the behavioral effects of Ditran. *Med Exp*, 8:15-27, 1963.

38. Lang W, Gershon S, Holan G. Some antagonists of atropine-like psychotomimetics. *J Pharm Pharmacol*, 15:831-840, 1963.
39. Lang WJ, Gershon S. The analeptic activity and EEG effects of some indole-alkaloids. *Psychiat Neurol*, 146:276-285, 1963.
40. Mackiewicz J, Gershon S. An experimental study of the neuropathological and toxicological effects of chlorpromazine and reserpine. *J Neuropsychiat*, 5:159-169, 1964.
41. Bell C, Gershon S, Carroll B, Holan G. Behavioral antagonism to a new psychotomimetic - JB 329. *Arch Int Pharmacodyn*, 147:3-25, 1964.
42. Gershon S, Lonigro A. A study of lymphocytes stained with Masson's Trichrome stain in psychiatric patients. *J Nerv Ment Dis*, 139:569-574, 1964.
43. Bell C, Gershon S. Experimental anticholinergic psychomimetics. Antagonism of yohimbine and Tacrine (THA). *Med Exp*, 10:15-21, 1964.
44. Itil T, Fink M, Neubauer H, Gershon S. Drug-induced dissolution of cortical electrical activity and its correlation with psychopathological phenomena. 4th Int. Meet Coll Internat Neuropsychopharmacol, Nov. 12, 1964.
45. Mackiewicz J, Gershon S. An experimental study of the neuropathological effects of imipramine in animals of different ages. *Int J Neuropsychiatry*, 1(6):608-15, 1965.
- 45b. Sletten IW, Pichardo X, Gershon S. Behavioral and pharmacological effects of a new psychoactive agent - IN1060. *Current Therapeutic Research*, 7(10):609-616, 1965.
46. Gershon S, Neubauer H, Sundland DM. Interaction between some anticholinergic agents and phenothiazines. Potentiation of phenothiazine sedation and its antagonism. *Clin Pharmacol Ther*, 6(6):749-56, 1965.
47. Brown MD, Lang WJ, Gershon S. Pharmacological and behavioral effects of 3,4-dimethoxyphenylethylamine in conscious and anesthetized animals. *Arch Int Pharmacodyn Ther*, 158(2):439-52, 1965.
48. Korol B, Lang WJ, Brown ML, Gershon S. Effects of chronic chlorpromazine administration on systemic arterial pressure in schizophrenic patients: Relationship of body position to blood pressure. *Clin Pharmacol Ther*, 6(5):587-91, 1965.
49. Sletten IW, Lang WJ, Brown MD, Ballou SR, Gershon S. Chronic chlorpromazine administration: Some pharmacological and psychological effects in man. *Clin Pharmacol Ther*, 6(5):575-86, 1965.
50. Gershon S. Behavioral effects of anticholinergic psychotomimetics and their antagonists in man and animals. *Recent Adv Biol Psychiatry*, 8:141-9, 1965.
51. Sletten IW, Gershon S. The premenstrual syndrome: A discussion of its pathophysiology and treatment with lithium ion. *Comprehensive Psychiatry*, 7(3):198-206, 1966.
52. Neubauer H, Sundland D, Gershon S. Ditrane and its antagonists in a mixed psychiatric population. *J Nerv Ment Dis*, 142(3):265-77, 1966.
53. Garfield SL, Gershon S, Sletten I, Neubauer H, Ferrel E. Withdrawal of ataractic medication in schizophrenic patients. *Dis Nerv Syst*, 27(5):321-5, 1966.

54. Neubauer H, Sundland DM, Gershon S. Sernyl, Ditrán, and their antagonists: Succinate and THA. *Int J Neuropsychiatry*, 2(3):216-22, 1966.
55. Neubauer H, Gershon S, Sundland DM. Differential responses to an anticholinergic psychotomimetic (Ditrán) in a mixed psychiatric population. *Psychiatr Neurol*, 151(2):65-80, 1966.
56. Nagy A, Gershon S. Clinical report on IN-1060. *Dis Nerv Syst*, 27(4):257-60, 1966.
57. Lang WJ, Brown ML, Gershon S, Sletten I, Korol B. Effects of chronic chlorpromazine administration upon the blood pressure responses to autonomic drugs in conscious dogs. *Arch Int Pharmacodyn Ther*, 162(2):330-44, 1966.
58. Brown ML, Gershon S, Lang WJ, Korol B. The effects of psychoactive drugs on the behavioral response to Ditrán in dogs. *Arch Int Pharmacodyn Ther*, 160(2): 407-23, 1966.
59. Korol B, Lang WJ, Brown ML, Gershon S. Pharmacological investigation of a new psychoactive agent. *Nature*, 209(29):1249-50, 1966.
60. Lang WJ, Korol B, Brown ML, Gershon S. Yohimbine analogues exhibiting differential pharmacological responses. *Med Pharmacol Exp*, 15(1):24-34, 1966.
61. Sletten IW, Gershon S. The effect of chlorpromazine on water and electrolyte balance. *J Nerv Ment Dis*, 142(1):25-31, 1966.
62. Lang WJ, Brown ML, Gershon S, Korol B. Classical and physiologic adaptive conditioned responses to anticholinergic drugs in conscious dogs. *Int J Neuropharmacol*, 5(4):311-14, 1966.
63. Brown ML, Gershon S, Korol B. Some pharmacological effects of a new potential antidepressant Cyprolidol (IN-1060) compared with imipramine. *Med Pharmacol Exp*, 15(4):329-43, 1966.
64. Sletten I, Pichardo J, Korol B, Gershon S. The effect of chlorpromazine on lithium excretion in psychiatric subjects. *Curr Ther Res*, 8(9):441-6, 1966.
65. Gershon S. Relations between animal and human effects of drug combinations. *Excerpta Med Int Cong Series*, 129:471-479, 1966.
66. Garfield S, Sletten I, Sundland D, Ballou SR, Gershon S. Chemically induced anxiety. *Int J Neuropsychiat*, 3(5):426-433, 1967.
67. Sletten I, Cazenave M, Gershon S. Effects of caloric restriction on behavior and body weight during chlorpromazine therapy. *Dis Nerv Syst*, 28(8):519-22, 1967.
68. Sletten IW, Pichardo J, Korol B, Sundland D, Gershon S. The results of alpha-adrenergic blockade on some behavioral and physiological effects of epinephrine. *Psychosom Med*, 29(5):504-13, 1967.
69. Gershon S, Hekimian LJ, Floyd A Jr, Hollister LE. Alpha-methyl-P-tyrosine (AMI) in schizophrenia. *Psychopharmacologia*, 11(2):189-94, 1967.
70. Hekimian LJ, Floyd A, Gershon S. Some clinical and physiological effects of a thioxanthene derivative (P-4657B) in twenty newly hospitalized male schizophrenics. *J Clin Pharmacol and J of New Drugs*, 7(1):52-57, 1967.
71. Angrist BM, Schweitzer J, Friedhoff AJ, Gershon S. Banana smoking. Chromatographic analysis of baked skins. *NY State J of Med*, 15, 67(22):2983-5, 1967.

72. Gershon S, Hekimian LJ, Floyd A Jr. Evaluation of a new antidepressant: A-10749. *J Clin Pharmacol*, 7(6):348-53, 1967.
73. Hekimian LJ, Floyd A, Gershon S. Clinical trial of an acridane derivative (SKF No. 14,336) in male schizophrenics. *Curr Ther Res*, 9(1):17-23, 1967.
74. Gershon S, Hekimian LJ, Floyd A. Preclinical-clinical correlation of anti-depressant activity: Controlled study of Gamfexine and Imipramine. *Curr Ther Res*, 9(7):349-54, 1967.
75. Angrist B, Gershon S. Drug-induced psychoses. *Hospital Practice Parts I and II*, 2:36-39,50-53, 1967.
76. Gershon S, Hekimian LJ, Floyd A. Non-correlation of preclinical-clinical evaluation of a proposed anti-depressant 4-Phenyl-Bicyclo (2,2,2) CCTAN-1-Amine Hydrochloride Monohydrate (Exp. 561). *Arzneim Forsch*, 18(2):243-5, 1968.
77. Gershon S. Use of lithium salts in psychiatric disorders. *Dis Nerv Syst*, 29(1):51-5, 1968.
78. Gershon S. The possible thymoleptic effect of the lithium ion. *Am J Psychiatry*, 124(10):1452-6, 1968.
79. Hekimian LJ, Gershon S. Characteristics of drug abusers admitted to a psychiatric hospital. *JAMA*, 205(3):125-30, 1968.
80. Sanghvi I, Bindler E, Gershon S. Pharmacology of a potential anti-Parkinson agent: Tigloidine. *Eur J Pharmacol*, 4(3):246-53, 1968.
81. Gershon S, Shopsin B, Bergen JR, Pinckney L. Reevaluation of heterophile hemolytic response in psychiatric patients. *Arch Gen Psychiatry*, 19(5):611-5, 1968.
82. Bindler E, Sanghvi I, Gershon S. Pharmacological and behavioral characteristics of 3-4, dimethoxyphenylethamine and its N-acetyl derivative. *Arch Int Pharmacodyn Ther*, 176(1):1-10, 1968.
83. Johnson G, Gershon S, Hekimian LJ. Controlled evaluations of lithium and chlorpromazine in the treatment of manic states: An interim report. *Compr Psychiatry*, 9(6):563-73, 1968.
84. Angrist BM, Gershon S, Floyd A. Psycho-activating effects of a new anticonvulsant--CM-6. *Curr Ther Res*, 10(5):237-43, 1968.
85. Hekimian LJ, Gershon S, Floyd A. Discrepancies in the evaluation of an antidepressant, BL-KR 140. *Curr Ther Res*, 10(6):282-7, 1968.
86. Gershon S. A review of the use of a thiazole derivative (Hemineurin) in delirium tremens and allied conditions. *Psychiatr Res Rep AM Psychiatr Assoc*, 24:166-73, 1968.
87. Hekimian LJ, Gershon S, Floyd A. Cyprolidol and imipramine: A double-blind controlled study in endogenous depression. *Arzneim Forsch*, 19(6):955-6, 1969.
88. Shopsin B, Gershon S, Pinckney L. The secretion of lithium in human mixed saliva: Effects of ingested lithium on electrolyte distribution in saliva and serum. *Int Pharmacopsychiat*, 2:148-169, 1969.
89. Sanghvi I, Gershon S. The evaluation of central nervous system stimulants in a new laboratory test for antidepressants. *Life Sci*, 8(9):449-57, 1969.

90. Angrist B, Gershon S. Amphetamine abuse in New York City 1966-68. *Seminars in Psychiatry*, 1:195-207, 1969.
91. Sanghvi I, Bindler E, Gershon S. The evaluation of new animal method for the prediction of clinical antidepressant activity. *Life Sci*, 8(1):99-106, 1969.
92. Shopsin B, Blum M, Gershon S. Lithium-induced thyroid disturbance: Case report and review. *Compr Psychiatry*, 10(3):215-23, 1969.
93. Hekimian LJ, Gershon S, Hardesty AS, Burdock EI. Drug efficacy and diagnostic specificity in manic depressive illness and schizophrenia. *Dis Nerv Syst*, 30(11):747-751, 1969.
94. Shopsin B, Gershon S. The effects of sera from psychiatric patients on guinea pig brain tissue respiration. *J Nerv Ment Dis*, 148(2):188-91, 1969.
95. Angrist BM, Schweitzer J, Friedhoff AJ, Gershon S, Hekimian LJ, Floyd A. The clinical symptomatology of amphetamine psychosis and its relationship to amphetamine levels in urine. *Int Pharmacopsychiat*, 2:125-139, 1969.
96. Shopsin B, Hekimian LJ, Gershon S, Floyd A. A controlled evaluation of haloperidol, chlorpromazine, and sodium amobarbital: Intramuscular short-term use in acute psychotic patients. *Curr Ther Res*, 11(9):561-73, 1969.
97. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis--preliminary observations. *Biol Psychiatry*, 2(2):95-107, 1970.
98. Angrist BM, Gershon S, Levitan SJ, Blumberg AG. Lithium-induced diabetes insipidus-like syndrome. *Compr Psychiatry*, 11(2):141-6, 1970.
99. Angrist BM, Schweitzer JW, Gershon W, Friedhoff AJ. Mephentermine psychosis: Misuse of the Wyamine inhaler. *Am J Psychiatry*, 126(9):1315-7, 1970.
100. Gershon S. On the pharmacology of marijuana. *Behav Neuropsychiatry*, 1(10):9-18, 1970.
101. Gershon S. Lithium in mania. *Clin Pharmacol Ther*, 11(2):168-87, 1970.
102. Gershon S. Psychopharmacology of the lithium ion (twenty years after). *Dis Nerv Syst*, 31(5):333-5, 1970.
103. Angrist BM, Schweitzer JW, Friedhoff AJ, Gershon S. Investigation of P-methoxyamphetamine excretion in amphetamine induced psychosis. *Nature*, 225(233):651-2, 1970.
104. Hekimian LJ, Gershon S, Floyd A. The clinical evaluation of four proposed antidepressants - Relationship to their animal pharmacology. *Int Pharmacopsychiatry*, 3:65-76, 1970.
105. Johnson G, Maccario M, Gershon S, Korein, J. The effects of lithium on electroencephalogram, behavior and serum electrolytes. *J Nerv Ment Dis*, 151(4):273-89, 1970.
106. Ho AK, Loh HH, Craves F, Hitzemann RJ, Gershon S. The effect of prolonged lithium treatment on the synthesis rate and turnover of monoamines in brain regions of rats. *Eur J Pharmacol*, 10(1):72-8, 1970.
107. Sanghvi I, Gershon S. Similarities between behavioral and pharmacological actions of yohimbine and 5 hydroxytryptophan in the conscious dog. *Eur J Pharmacol*, 11(2):125-9, 1970.

108. Ho AK, Gershon S, Pinckney L. The effects of acute and prolonged lithium treatment on the disturbance of electrolytes, potassium and sodium. *Arch Int Pharmacodyn Ther*, 186(1):54-65, 1970.
109. Willner JH, Samach M, Angrist BM, Wallach MB, Gershon S. Drug-induced stereotyped behavior and its antagonism in dogs. *Comm In Behavioral Biology*, 5:135-141, 1970.
110. Sanghvi I, Urquiaga X, Gershon S. The effect of acute and chronic lithium administration on the superior cervical ganglion of the cat. *Pharmacological Research Communications*, 2(4):361-368, 1970.
111. Shopsin B, Johnson G, Gershon S. Neurotoxicity with lithium: Differential drug responsiveness. *Int Pharmacopsychiat*, 5:170-182, 1970.
112. Gershon S, Hekimian LJ, Burdock EI, Kim SS. Antipsychotic properties of loxapine succinate. *Curr Ther Res*, 12(5):280-5, 1970.
113. Gershon S, Hekimian LJ, Burdock EI, Park S, Floyd A. Relative efficacy of butaperazine and chlorpromazine in acute schizophrenia. *Curr Ther Res*, 12(12):810-8, 1970.
114. Bindler EH, Wallach MB, Gershon S. Effect of lithium on the release of ¹⁴C-Norepinephrine by nerve stimulation from the perfused cat spleen. *Arch Int Pharmacodyn Ther*, 190(1):150-4, 1971.
115. Wallach MB, Gershon S. A neuropsychopharmacological comparison of D-amphetamine, L-dopa and cocaine. *Neuropharmacology*, 10(6):743-52, 1971.
116. Shopsin B, Gershon S. Plasma cortisol response to dexamethasone suppression in depressed and control patients. *Arch Gen Psychiatry*, 24(4):320-6, 1971.
117. Johnson G, Gershon S, Burdock EI, Floyd A, Hekimian L. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. *Br J Psychiatry*, 119(550):267-76, 1971.
118. Singer G, Ho A, Gershon S. Changes in activity of choline acetylase in central nervous system of rat after intraventricular administration of Noradrenaline. *Nature New Biol*, 230(13):152-3, 1971.
119. Angrist B, Gershon S. A pilot study of pathogenic mechanisms in amphetamine psychosis utilizing differential effects of D and L amphetamine. *Pharmakopsychiatrie Neuro-Psychopharmakologie*, 4(2):65-75, 1971.
120. Shopsin B, Kim SS, Gershon S. A controlled study of lithium vs. chlorpromazine in acute schizophrenics. *Br J Psychiatry*, 119(551):435-40, 1971.
121. Gershon S. Lithium. *Ration Drug Ther*, 7(5):1-5, 1971.
122. Sanghvi I, Urquiaga X, Gershon S. Exploration of the anti-depressant potential of L-dopa. *Psychopharmacologia*, 20(2):118-27, 1971.
123. Floyd A Jr, Gershon S. An investigation of the anti-anxiety properties of oxilapine. (Administered to normal volunteers). *Dis Nerv Syst*, 32(8):559-64, 1971.
124. Schweitzer JW, Friedhoff AJ, Angrist BM, Gershon S. Excretion of P-methoxyamphetamine administered to humans. *Nature*, 229(280):133-4, 1971.
125. Ho AK, Singer G, Gershon S. Biochemical evidence of adrenergic interaction with cholinergic function in the central nervous system of the rat 1. Effect of norepinephrine. *Psychopharmacologia*, 21(3):238-46, 1971.

126. Angrist BM, Shopsin B, Gershon S. Comparative psychotomimetic effects of stereoisomers of amphetamine. *Nature*, 234(325):152-3, 1971.
127. Wallach MB, Angrist BM, Gershon S. The comparison of the stereotyped behavior-inducing effects of d- and l-amphetamine in dogs. *Comm Behav Biol*, 6(2): 93-6, 1971.
128. Shopsin B, Friedmann R, Gershon S. Lithium and leukocytosis. *Clin Pharmacol Ther*, 12(6):923-8, 1971.
129. Singer G, Sanghvi I, Gershon S. Exploration of certain behavioral patterns induced by psychoactive agents in the rat. *Communications in Behavioral Biology*, 6:307-314, Abstract No. 07710042, 1971.
130. Sanghvi I, Gershon S. Differential behavioral and biochemical effects of yohimbine over time of administration. *Psychopharmacol Bull*, 7(4):32, 1971.
131. Johnson G, Gershon S. Differential response to psychotropic drugs. *Compr Psychiatry*, 12(5):399-413, 1971.
132. Ho A, Hoffman DB, Gershon S, Loh HH. Distribution and metabolism of tritiated yohimbine in mice. *Arch Int Pharmacodyn Ther*, 194(2):304-15, 1971.
133. Sanghvi I, Shopsin B, Gershon S. The effects of sub-acute administration of triiodothyronine (T₃) on the acute toxicity of lithium in the rat. *Life Sci*, 10(1):1217-1223, 1971.
134. Ho AKA, Gershon S. The effects of lithium on the metabolism and distribution of electrolytes. *Dis of the Nerv System*, 504, 1971.
135. Ho AKA, Loh HH, Gershon S. The effects of prolonged lithium treatment on biogenic amines synthesis in discrete areas of the rat brain. *Dis of the Nerv System*, 504-505, 1971.
136. Shopsin B, Wilk S, Gershon S, Green J, Davis K. Catecholamines and affective disorders: Levels of M.H.P.G. in CSF. *Pharmacologist*, 39:398, 1971.
137. Wallach MB, Gershon S. Sensitization to amphetamines. *Psychopharmacol Bull*, 7(4):30-1, 1971.
138. Gershon S. Megavitamins in schizophrenia. *California Medicine (The Western J. of Medicine)*, 45, 1971.
139. Park S, Glick B, Floyd A, Gershon S. Ketipramine fumarate as compared to imipramine in depressed outpatients. *Curr Ther Res*, 13(5):322-5, 1971.
140. Elizur A, Gershon S. Evaluation of the antipsychotic activity of an indole analogue, AL-1612. *Curr Ther Res*, 13(9):584-90, 1971.
141. Shopsin B, Stern S, Gershon S. Altered carbohydrate metabolism during treatment with lithium carbonate. Absence of diagnostic specificity in hospitalized psychiatric patients. *Arch Gen Psychiatry*, 26(6):566-571, 1972.
142. Ho AK, Gershon S. Drug-induced alterations in the activity of rat brain cholinergic enzymes. I. In vitro and in vivo effect of amphetamine. *Eur J Pharmacol*, 18(2):195-200, 1972.
143. Gershon S. Lithium salts in the management of the manic-depressive syndrome. *Annu Rev Med*, 23:439-52, 1972.

144. Wilk S, Shopsin B, Gershon S, Suhl M. Cerebrospinal fluid levels of MHPG in affective disorders. *Nature*, 235(339):440-1, 1972.
145. Friedman E, Gershon S. L-dopa: centrally mediated emission of seminal fluid in male rats. *Life Sci*, 11(9):435-40, 1972.
146. Friedman E, Gershon S. Increased NE synthesis in food-deprived rats. *Eur J Pharmacol*, 17(2):259-269, 1972.
147. Park S, Burdock EK, Gershon S. Importance of adequate dosage determination of drug efficacy: Trial of a new butyrophenone compound on acute schizophrenics. *Pharmakopsychiatrie Neuro-Psychopharmakologie*, 5(4):191-197, 1972.
148. Wallach MB, Friedman E, Gershon S. 2,5-dimethoxy-4-methylamphetamine (DOM), a neuropharmacological examination. *J Pharmacol Exp Ther*, 182(1):145-54, 1972.
149. Wallach MB, Gershon S. The induction and antagonism of central nervous system stimulant-induced stereotyped behavior in the cat. *Eur J Pharmacol*, 18(1):22-26, 1972.
150. Angrist B, Shopsin B, Gershon S, Wilk S. Metabolites of monoamines in urine and cerebrospinal fluid, after large dose amphetamine administration. *Psychopharmacologia*, 26(1):1-9, 1972.
151. Dunkley B, Sanghvi I, Friedman E, Gershon S. Comparison of behavioral and cardiovascular effects of L-dopa and 5-HTP in conscious dogs. *Psychopharmacologia*, 26: 161-172, 1972.
152. Elizur A, Shopsin B, Gershon S, Ehlenberger A. Intra:extracellular lithium ratios and clinical course in affective states. *Clin Pharmacol Ther*, 13(6):947-53, 1972.
153. Shopsin B, Freedman LS, Goldstein M, Gershon S. Serum dopamine-B-hydroxylase (DBH) activity and affective states. *Psychopharmacologia*, 27(1):11-16, 1972.
154. Rotrosen J, Wallach MB, Angrist B, Gershon S. Antagonism of apomorphine-induced stereotypy and emesis in dogs by thioridazine, haloperidol, and pimozide. *Psychopharmacologia*, 26(2):185-94, 1972.
155. Rotrosen J, Angrist BM, Wallach MB, Gershon S. Absence of serotonergic influence on apomorphine-induced stereotypy. *Eur J Pharmacol*, 20(1):133-5, 1972.
156. Wallach MB, Friedman E, Gershon S. Behavioral and neurochemical effects of psychotomimetic drugs in neonate chicks. *Eur J Pharmacol*, 17(2):259-69, 1972.
157. Friedman E, Gershon S. L-dopa and imipramine: biochemical and behavioral interaction. *Eur J Pharmacol*, 18(2):183-8, 1972.
158. Park S, Gershon S, Angrist B, Floyd A. Evaluation of an aminotetraline, CP 14.368, as an antidepressant. *Curr Ther Res*, 14(2):65-70, 1972.
159. Park S, Gershon S, Floyd A. A clinical trial of a benzazepine (SCH 12679) in acute schizophrenic patients. *Curr Ther Res*, 14(6):298-302, 1972.
160. Sathananthan G, Park S, Lee HK, Gershon S. Clinical evaluation of two proposed antidepressants. *Curr Ther Res*, 14(22):711-15, 1972.
161. Shopsin B, Pearson E, Gershon S, Collins P. A controlled double-blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients. *Curr Ther Res*, 14(11):739-48, 1972.

162. Klingenstein RJ, Wallach MB, Gershon S. A comparison of pimozide and thioridazine as antagonists of amphetamine-induced stereotyped behavior in dogs. *Arch Int Pharmacodyn Ther*, 203(1):67-71, 1973.
163. Friedman E, Starr N, Gershon S. Catecholamine synthesis and the regulation of food intake in the rat. *Life Sci*, 12(7):317-26, 1973.
164. Sakalis G, Chan TL, Gershon S, Park S. The possible role of metabolites in therapeutic response to chlorpromazine treatment. *Psycho-pharmacologia*, 32(3):279-84, 1973.
165. Sanghvi I, Gershon S. Rubidium and lithium: Evaluation as anti-depressant and anti-manic agents. *Res Commun Chem Pathol Pharmacol*, 6(1):293-300, 1973.
166. Angrist B, Gershon S. Behavioral profile of a potent new psychotoxic compound. *Psychopharmacologia*, 30(2):109-16, 1973.
167. Chan TL, Gershon S. Chlorpromazine metabolism in humans. Part I. Quantitation of chlorpromazine and its metabolites in human plasma and urine by direct scan spectrodensitometry. *Mikrochimica Acta*, 435-452, 1973.
168. Shopsin B, Sathananthan GL, Chan TL, Kravitz H, Gershon S. Antinuclear factor in psychiatric patients. *Biol Psychiatry*, 7(2):81-7, 1973.
169. Wallach MB, Rotrosen J, Gershon S. A neuropsychopharmacological study of phenmetrazine in several animal species. *Neuropharmacology*, 12(6):541-8, 1973.
170. Wallach MB, Gershon S. The effects of delta8-THC on the EEG, reticular multiple unit activity and sleep of cats. *Eur J Pharmacol*, 24(2):172-8, 1973.
171. Geyer H, Sanghvi I, Gershon S. Exploration of the anti-depressant potential of lithium. *Psychopharmacologia*, 28(2):107-13, 1973.
172. Sanghvi I, Geyer HM, Gershon S. The effect of lithium on adrenergic function in dog. *Life Sci*, 12(8):337-44, 1973.
173. Shopsin B, Sathananthan G, Gershon S. Plasma renin response to lithium in psychiatric patients. *Clin Pharmacol Ther*, 14(4):561-4, 1973.
174. Angrist B, Sathananthan G, Gershon S. Behavioral effects of L-dopa in schizophrenic patients. *Psychopharmacologia*, 31(1):1-12, 1973.
175. Sathananthan G, Shopsin B, Gershon S. The effects of lithium carbonate on serum gastrin in psychiatric patients. *Res Commun Chem Pathol Pharmacol*, 5(3):875-8, 1973.
176. Friedman E, Gershon S. Effect of lithium on brain dopamine. *Nature*, 243(109):520-1, 1973.
177. Sathananthan GL, Gershon S. Imipramine withdrawal: an akathisia-like syndrome. *Am J Psychiatry*, 130(11):1286-7, 1973.
178. Sathananthan G, Angrist BM, Gershon S. Response threshold to levodopa in psychiatric patients. *Biol Psychiatry*, 7(2):139-46, 1973.
179. Friedman E, Friedman J, Gershon S. Dopamine synthesis: Stimulation by a hypothalamic factor. *Science*, 182(114):831-2, 1973.

180. Shopsin B, Wilk S, Gershon S, Davis K, Suhl M. Cerebrospinal fluid MHPG. An assessment of norepinephrine metabolism in affective disorders. *Arch Gen Psychiatry*, 28(2):230-3, 1973.
181. Hine B, Sanghvi I, Gershon S. Evaluation of thyrotropin-releasing hormone as a potential antidepressant agent in the conscious dog. *Life Sci*, 13(12):1789-97, 1973.
182. Sathananthan G, Gershon S. Renal damage due to imipramine. *Lancet*, 1(807):833-4, 1973.
183. Gershon S. The effects of lithium on autonomic function in dog. *Life Sci*, 12:337-44, 1973.
184. Gershon S. Pediatric psychopharmacology - Clinical laboratory standards. *Psychopharmacol Bull*, Special Issue, *Pharmacotherapy of Children*, pg. 167, 1973.
185. Angrist B, Park S, Urcoyo L, Roffman M, Gershon S. Clinical evaluation of a possible catechol-o-methyl transferase inhibitor in endogenous depression. *Curr Ther Res*, 15(3):127-32, 1973.
186. Sakalis G, Pearson E, Kermani E, Gershon S. On the anti-anxiety properties of a new benzodiazepine, ORF 8063. *Curr Ther Res*, 15(5):268-71, 1973.
187. Sathananthan GL, Matz R, Thompson H, Gershon S. Amoxapine and imipramine: A double-blind study in depressed patients. *Curr Ther Res*, 15(12):919-22, 1973.
188. Angrist BM, Wilk S, Gershon S. The effect of probenecid and large dose amphetamine administration on cerebrospinal fluid homovanillic acid. *Biol Psychiatry*, 8(1): 113-4, 1974.
189. Angrist B, Sathananthan G, Wilk S, Gershon S. Amphetamine psychosis: Behavioral and biochemical aspects. *J Psychiat Res*, 2:13-23, 1974.
190. Angrist B, Lee HK, Gershon S. The antagonism of amphetamine-induced symptomatology by a neuroleptic. *Am J Psychiatry*, 131(7):817-19, 1974.
191. Chan TL, Sakalis G, Gershon S. Quantitation of chlorpromazine and its metabolites in human plasma and urine by direct spectrodensitometry of thin-layer chromatograms. *Adv Biochem Psychopharmacol*, 9(0):323-33, 1974.
192. Angrist B, Urcoyo L, Gershon S. Response to incremental doses of Ditrin in abstinent alcoholics and drug users. *Compr Psychiatry*, 15(3):201-4, 1974.
193. Angrist B, Rotrosen J, Gershon S. Assessment of tolerance to the hallucinogenic effects of DOM. *Psychopharmacologia*, 36(3):203-7, 1974.
194. Gershon S, Shopsin B. (Guest editors): Amines and affective state. *J Nerv Ment Dis*, (Suppl.) 158(5), 1974.
195. Gershon S. Lithium prophylaxis in recurrent affective disorders. *Compr Psychiatry*, 15(5):365-73, 1974.
196. Angrist B, Gershon S. Dopamine and psychotic states: Preliminary remarks. *Adv Biochem Psychopharmacol*, 12(0):211-9, 1974.
197. Friedman E, Shopsin B, Sathananthan G, Gershon S. Blood platelet monoamine oxidase activity in psychiatric patients. *Am J Psychiatry*, 131(12):1392-4, 1974.
198. Sanghvi I, Gershon S. Yohimbine: Behavioral and biochemical effects in mice. *Arch Int Pharmacodyn Ther*, 210(1):108-20, 1974.

199. Shopsin B, Wilk S, Sathananthan G, Gershon S, Davis K. Catecholamines and affective disorders revised: A critical assessment. *J Nerv Ment Dis*, 158(5):369-83, 1974.
200. Friedman E, Shopsin B, Goldstein M, Gershon S. Interactions of imipramine and synthesis inhibitors on biogenic amines. *J Pharm Pharmacol*, 26(12):995-6, 1974.
201. Friedman E, Gershon S. Effect of delta8-THC on alcohol-induced sleeping time in the rat. *Psychopharmacologia*, 39(3):193-8, 1974.
202. Wallach MB, Hine B, Gershon S. Cross tolerance or tachyphylaxis among various psychotomimetic agents on cats. *Eur J Pharmacol*, 29(1):89-92, 1974.
203. Shopsin B, Gershon S. The current status of lithium in psychiatry. *Am J Med Sci*, 268(6):306-23, 1974.
204. Sathananthan G, Petersson B, Shopsin B, Gershon S. The effects of lithium carbonate on serum gastrin in psychiatric patients. *Acta Psychiat Scand*, 50:86-89, 1974. (See also 192).
205. Sakalis G, Oh D, Gershon S, Shopsin B. A trial of gerovital H-3 in depression during senility. *Curr Ther Res*, 16(1):59-63, 1974.
206. Angrist BM, Gershon S. Proceedings: Dopamine and psychiatric states: Preliminary remarks. *Psychopharmacol Bull*, 10(3):15, 1974.
207. Sathananthan GL, Angrist BM, Phillips N, Gershon S. Assessment of antipsychotic activity of a butyrophenone analogue, lenperone (AHR 2277). *Curr Ther Res*, 16(8):844-7, 1974.
208. Sakalis G, Sathananthan G, Collins P, Gershon S. SQ 65,396: a non-sedative anxiolytic? *Curr Ther Res*, 16(8):861-3, 1974.
209. Gershon S. Lithium carbonate for manic-depressive states. *Am Fam Physician*, 10(4):196-8, 1974.
210. Sathananthan G, Rick W, Matz R, Angrist B, Gershon S. Psychomotor effects of a new CSN stimulant, Abbott 34519. *Curr Ther Res*, 16(11):1177-80, 1974.
211. Matz R, Rick W, Thompson H, Gershon S. Clozapine -- A potential antipsychotic agent without extrapyramidal manifestations. *Curr Ther Res*, 16(7):687-95, 1974.
212. Gershon S. Predicting psychotropic drug activity from pre-clinical models (animal and human). *Psychopharm Bull*, 10:20-22, 1974.
213. Shopsin B, Friedman E, Gershon S, Goldstein M. Proceedings: Drugs, Mood, and Amines: A profile in psychobiological research. *Psychopharm Bull*, 10(4):52, 1974.
214. Borg J, Gershon S, Alpert M. Dose effects of smoked marihuana on human cognitive and motor functions. *Psychopharmacologia*, 42(3):211-8, 1975.
215. Hine B, Wallach MB, Gershon S. Involvement of biogenic amines in drug-induced aggressive pecking in chicks. *Psychopharmacologia*, 43(3):215-21, 1975.
216. Shopsin B, Hirsch J, Gershon S. Visual hallucinations and propranolol. *Biol Psychiatry*, 10(1):105-7, 1975.
217. Shopsin B, Janowsky D, Davis J, Gershon S. Rebound phenomena in manic patients following physostigmine. Preliminary observations. *Neuro-psychobiology*, 1(3):180-7, 1975.

218. Tadepalli AS, Friedman E, Gershon S. Cardiovascular actions of 2,5-dimethoxy-4-methylamphetamine (DOM) in the cat. *Eur J Pharmacol*, 31(2):305-12, 1975.
219. Shopsin B, Gershon S, Thompson H, Collins P. Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. *Arch Gen Psychiatry*, 32(1):34-42, 1975.
220. Sanghvi IS, Singer G, Friedman E, Gershon S. Anorexigenic effects of D-amphetamine and L-dopa in the rat. *Pharmacol Biochem Behav*, 3(1):81-6, 1975.
221. Friedman E, Gershon S, Rotrosen J. Effects of acute cocaine treatment on the turnover of 5-hydroxytryptamine in the rat brain. *Br J Pharmacol*, 54(1):61-4, 1975.
222. Shopsin B, Gershon S. Cogwheel rigidity related to lithium maintenance. *Am J Psychiatry*, 132(5):536-8, 1975.
223. Hine B, Friedman E, Torrelío M, Gershon S. Morphine-dependent rats: Blockade of precipitated abstinence by tetrahydrocannabinol. *Science*, 187(4175):443-5, 1975.
224. Hine B, Friedman E, Torrelío M, Gershon S. Tetrahydrocannabinol - Attenuated abstinence and induced rotation in morph-dependent rats: Possible involvement of dopamine. *Neuropharmacology*, 14(8):607-10, 1975.
225. Sanghvi I, Gershon S. Effect of acute and chronic iprindole on serotonin turnover in mouse brain. *Biochem Pharmacol*, 24(22):2103-4, 1975.
226. Shopsin B, Gershon S, Goldstein M, Friedman E, Wilk S. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. *Psychopharmacol Commun*, 1(2):239-49, 1975.
227. Rotrosen J, Friedman E, Gershon S. The search for the dopamine receptor: Tribulations. *Psychopharmacol Commun*, 1(2):229-37, 1975.
228. Angrist B, Thompson F, Shopsin B, Gershon S. Clinical studies with dopamine-receptor stimulants. *Psychopharmacologia*, 44(3):273-80, 1975.
229. Hine B, Torrelío M, Gershon S. Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC. *Psychopharmacol Commun*, 1(3):275-83, 1975.
230. Hine B, Torrelío M, Gershon S. Differential effect of cannabiniol and cannabidiol on THC-induced responses during abstinence in morph-dependent rats. *Res Commun Chem Pathol Pharmacol*, 12(1):185-8, 1975.
231. Sanghvi I, Shopsin B, Gershon S. The influence of dietary iodine on lithium blood level, Serum T4 and thyroid gland weight. *Psychopharmacol Commun*, 1(4):437-44, 1975.
232. Lambert B, Friedman E, Gershon S. Centrally-mediated cardiovascular responses to 5-HT. *Life Sci*, 17(6):915-9, 1975.
233. Rotrosen J, Friedman E, Gershon S. Striatan adenylate cyclase activity following reserpine and chronic chlorpromazine administration in rats. *Life Sci*, 17(4):563-8, 1975.
234. Hine B, Torrelío M, Gershon S. Interactions between cannabidiol and delta 9-THC during abstinence in morph-dependent rats. *Life Sci*, 17(6):851-7, 1975.

235. Friedman E, Rotrosen J, Gurland M, Lambert GA, Gershon S. Enhancement of reserpine-elicited dopaminergic supersensitivity by repeated treatment with apomorph and alpha-methyl-P-tyrosine. *Life Sci*, 17(6):867-73, 1975.
236. Sathananthan GL, Gershon S, Lenn E. Psychological profiles and effects in acute trauma: A pilot study. *Dis Nerv Syst*, 36(1):17-19, 1975.
237. Matz R, Rick W, Oh C, Thompson H, Gershon S. Clozapine -- a potential antipsychotic agent without extrapyramidal manifestations. *Psychopharmacol Bull*, 11(1):14, 1975.
238. Sathananthan GL, Sanghvi I, Phillips N, Gershon S. MJ 9022: Correlation between neuroleptic potential and stereotypy. *Curr Ther Res*, 18(5):701-5, 1975.
239. Angrist BM, Sathananthan G, Thompson H, Gershon S. A clinical trial of a structurally unique neuroleptic (SU-23397). *Curr Ther Res*, 18(2):359-63, 1975.
240. Gershon S, Angrist B, Shopsin B. Drugs, diagnosis and disease. *Res Publ Assoc Res Nerv Ment Dis*, 54:85-100, 1975.
241. Sathananthan GL, Gershon S, Almeida M, Spector N, Spector S. Correlation between plasma and cerebrospinal levels of imipramine. *Arch Gen Psychiatry*, 33(9):1109-10, 1976.
242. Angrist B, Gershon S. Clinical effects of amphetamine and L-dopa on sexuality and aggression. *Compr Psychiatry*, 17(6):715-22, 1976.
243. Angrist B, Gershon S, Sathananthan G, Walker RW, Lopez-Ramos B, Mandel LR, Vandenneuvel WJ. Dimethyltryptamine levels in blood of schizophrenic patients and control subjects. *Psychopharmacologia*, 47(1):29-32, 1976.
244. Friedman E, Hanin I, Gershon S. Effect of tetrahydrocannabinols on 3H-acetylcholine biosynthesis in various rat brain slices. *J Pharmacol Exp Ther*, 196(2):339-45, 1976.
245. Sanghvi IS, Gershon S. Morphine dependent rats: blockade of precipitated abstinence by calcium. *Life Sci*, 18(6):649-54, 1976.
246. Sanghvi IS, Geyer H, Gershon S. Exploration of the antidepressant potential of iprindole. *Life Sci*, 18(6):569-74, 1976.
247. Shopsin B, Friedman E, Gershon S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. *Arch Gen Psychiatry*, 33(7):811-9, 1976.
248. Traficante LJ, Friedman E, Oleshansky MA, Gershon S. Dopamine-sensitive adenylate cyclase and camp phosphodiesterase in substantia nigra and corpus striatum of rat brain. *Life Sci*, 19(7):1061-6, 1976.
249. Rotrosen J, Angrist BM, Gershon S, Sachar EJ, Halpern FS. Dopamine receptor alteration in schizophrenia: Neuroendocrine evidence. *Psychopharmacology*, 51(1):1-7, 1976.
250. Friedman E, Shopsin B, Gershon S. Effects of tranylcypromine CN 5-HT uptake and its interactions with PCPA on rat brain 5-HT. *Res Commun Chem Pathol Pharmacol*, 15(1):191-4, 1976.
251. Suslak L, Shopsin B, Silbey E, Mendlewicz J, Gershon S. Genetics of affective disorders. I. Familial incidence study of bipolar, unipolar and schizo-affective illnesses. *Neuropsychobiology*, 2(1):18-27, 1976.

252. Shopsin B, Mendlewicz J, Suslak L, Silbey E, Gershon S. Genetics of affective disorders. II. Morbidity risk and genetic transmission. *Neuropsychobiology*, 2(1):28-36, 1976.
253. Ferris SH, Sathananthan G, Gershon S, Clark C, Moshinsky J. Cognitive effects of ACTH 4-10 in the elderly. *Pharmacol Biochem Behav*, 5(1):73-8, 1976.
254. Ferris S, Crook T, Sathananthan G, Gershon S. Reaction time as a diagnostic measure in senility. *J Am Geriat Soc*, 24(12):529-33, 1976.
255. Gershon S, Shopsin B, Wilk S. Exploration of affective illness. *Neuropsychobiology*, 2(2-3):145-60, 1976.
256. Angrist B, Rotrosen J, Aronson M, Gershon S. A morphanthridine derivative in schizophrenic patients--lack of extrapyramidal symptoms. *Curr Ther Res*, 20(1):94-8, 1976.
257. Sathananthan G, Mir P, Minn FL, Gershon S. Antidepressant predictability: cartazolate. *Curr Ther Res*, 19(4):475-8, 1976.
258. Sathananthan G, Mir P, Gershon S. Antipsychotic effects of AL 1965. *Curr Ther Res*, 19(5):516-19, 1976.
259. Friedman E, Gershon S, Hine B, Torrello M. Cardiovascular effects of delta 9-tetrahydrocannabinol in conscious and anesthetized dogs. *Br J Pharmacol*, 59(4):561-3, 1977.
260. Angrist B, Gershon S. Clinical response to several dopamine agonists in schizophrenic and non-schizophrenic subjects. *Adv Biochem Psychopharmacol*, 16:677-80, 1977.
261. Sanghvi IS, Gershon S. Commentary: Brain calcium and morph action. *Biochem Pharmacol*, 26(13):1183-5, 1977.
262. Traficante LJ, Hine B, Gershon S, Sakalis G. Chloroquine potentiation of thioridazine effects in rats and drug-resistant schizophrenic patients: A preliminary report. *Commun Psychopharmacol*, 1(4):407-19, 1977.
263. Hine B, Torellio M, Gershon S. Analgesic, heart rate, and temperature effects of delta 8 - THC during acute and chronic administration to conscious rats. *Pharmacology*, 15(1):63-72, 1977.
264. Rotrosen J, Angrist BM, Gershon S, Sachar EJ, Halpern FS. Neuroendocrine assessment of dopaminergic activity in schizophrenia. *Adv Biochem Psychopharmacol*, 16:649-53, 1977.
265. Sakalis G, Chan TL, Sathananthan G, Schooler N, Goldberg S, Gershon S. Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. *Commun Psychopharmacol*, 1(2):157-66, 1977.
266. Hine B, Gershon S. Haloperidol attenuation of morphine abstinence: Synergistic effect of acute lithium administration. *J Pharm Pharmacol*, 29(4):238-40, 1977.
267. Angrist B, Rotrosen J, Kleinberg D, Merriam V, Gershon S. Dopaminergic agonist properties of ephedrine - Theoretical Implications. *Psychopharmacology*, 55(2):115-20, 1977.
268. Crook T, Ferris S, Sathananthan G, Raskin A, Gershon S. The effect of methylphenidate on test performance in the cognitively impaired aged. *Psychopharmacology*, 52(3):251-5, 1977.
269. Ferris SH, Sathananthan G, Gershon S, Clark C. Senile dementia: treatment with deanol. *J Am Geriat Soc*, 25(6):241-4, 1977.

270. Friedman E, Fung F, Gershon S. Antidepressant drugs and dopamine uptake in different brain regions. *Eur J Pharmacol*, 42(1):47-51, 1977.
271. Sathananthan GL, Ferris S, Gershon S. Psychopharmacology of aging: Current trends. *Curr Dev Psychopharmacol*, 4:249-64, 1977.
272. Gershon S. Generalist's guide to manic depressive illness. *Current Prescribing*, 3(3):70-75, 1977.
273. Raskin A, Gershon S, Crook TH. The effects of hyper- and normobaric oxygen on cognitive impairment in the elderly. *Proceedings. Psychopharm Bull*, 13(20):45-6, 1977.
274. Sakalis G, Traficante L, Gershon S. Thioridazine metabolism and clinical response: A pilot study. *Curr Ther Res*, 21(5):720-24, 1977.
275. Rotrosen J, Angrist BM, Gershon S, Aronson M, Gruen P, Sachar EJ, Denning RK, Matthyse S, Stanley M, Wilk S. Thiethylperazine: Clinical antipsychotic efficacy and correlation with potency in predictive systems. *Arch Gen Psychiatry*, 35:1112-1118, 1978.
276. Rotrosen J, Angrist B, Clark C, Gershon S, Halpern FS, Sachar EJ. Suppression of prolactin by dopamine agonists in schizophrenics and controls. *Am J Psychiatry*, 135(8):949-951, 1978.
277. Shopsin B, Gershon S. Dopamine receptor stimulation in the treatment of depression: Piribedil (Ed-495). *Neuropsychobiology*, 4:1-14, 1978.
278. Traficante LJ, Shenkman L, Rotrosen J, Gershon S. Stimulation of the membrane-bound, magnesium-dependent adenosine triphosphatase of mouse neuroblastoma by concanavalin A and wheat germ agglutinin. *Life Sciences*, 22(12):1059-1066, 1978.
279. Rotrosen J, Angrist B, Paquin J, Gurland M, Gershon S. Neuroendocrine studies with dopamine agonists in schizophrenia. *Psychopharm Bull*, 14:14-17, 1978.
280. Burdock EI, Hardesty AS, Frosch WA, Gershon S, Grec P. A comparison of psychiatric and psychological assessments of acute schizophrenics. *Applied Psychological Measurement*, 1(2):175-187, 1978.
281. Lambert GA, Friedman E, Buchweitz E, Gershon S. Involvement of 5-hydroxytryptamine in the central control of respiration, blood pressure and heart rate in the anaesthetized rat. *Neuropharmacology*, 17:807-813, 1978.
282. Shenkman L, Traficante LJ, Rotrosen J, Gershon S. Effects of lithium on the membrane-bound magnesium-dependent ATPase of mouse neuroblastoma cells. *Communications in Psychopharmacology*, 2:65-72, 1978.
283. Rotrosen J, Miller AD, Mandio D, Traficante LJ, Gershon S. Reduced PGE₁ stimulated ³H-cAMP accumulation in platelets from schizophrenics. *Life Sci*, 23(20):1989-1996, 1978.
284. Lambert GA, Lang WJ, Friedman E, Meller E, Gershon S. Pharmacological and biochemical properties of isomeric yohimbine alkaloids. *Eur J of Pharmacol*, 49(1):39-48, 1978.
285. Rotrosen J, Traficante LJ, Conner B, Basuk P, Gershon S. Effects of plant lectins on cation-activated brain ATPases. *Life Sci*, 23(12):1241-1247, 1978.
286. Raskin A, Gershon S, Crook TH, Sathananthan G, Ferris S. The effects of hyperbaric and normobaric oxygen on cognitive impairment in the elderly. *Arch Gen Psychiatry*, 35:50-56, 1978.

287. Gershon S, Shopsin B, Wilk S. Exploration of affective illness. Asilomar Conference on Neurotransmitters and Hypotheses of Psychiatric Disorder, January 13-16, 1976. *Neuropsychology*, 2(2):31-45, 1976, and Proceedings of the 10th C.I.N.P., July 1976:761-772, 1978. New York: Pergamon Press.
288. Angrist B, Gershon S. Four dopamine agonists: A clinical continuum. Presented at the CINP Meeting, Quebec, Canada, 10th Congress, 1976. In: Proceedings of the 10th Congress of the C.I.N.P., Quebec, July, 1976, ed. by P. Deniker, C. Radouco-Thomas and A. Villeneuve. New York: Pergamon Press, 1978. 731-738.
289. Gershon S. Lithium and the kidney. *The SK&F Eskalith Newsletter*,3(4), 1978.
290. Angrist B, Gershon S. Variable attenuation of amphetamine effects by lithium. *Am J Psychiatry*, 136(6):806-810, 1979.
291. Rotrosen J, Angrist B, Gershon S, Pacquin J, Branchey L, Oleshansky M, Halpern F, Sachar EJ. Neuroendocrine effects of apomorp: Characterization of response patterns and application to schizophrenia research. *Brit J Psychiat*, 235:444-456, 1979.
292. Lautin A, Angrist B, Gershon S, Stanley M. Extrapyramidal syndrome with sodium valproate. *Brit Med J*, 2:1035-1036, 1979.
293. Hine B, Traficante LJ, Sakalis G, Gershon S. Thioridazine and EKG anomalies. *Experientia*, 35(12):1631-1632, 1979.
294. Angrist B, Ain J, Rotrosen J, Gershon S, Halpern FS, Sachar EJ. Behavioral and neuroendocrine effects of low dose ET-495: Antagonism by haloperidol. *J Neural Transmission*, 44:249-262, 1979.
295. Traficante LJ, Siekierski J, Sakalis G, Gershon S. Sulfoxidation of chlorpromazine and thioridazine by bovine liver - preferential metabolic pathways. *Biochemical Pharmacology*, 28:621-626, 1979.
296. Traficante LJ, Sakalis G, Siekierski J, Rotrosen J, Gershon S. Rapid *in vivo* sulfoxidation of chlorpromazine by human blood: Inhibition by an endogenous plasma protein factor. *Life Sci*, 24(4):337-345, 1979.
297. Georgotas A, Gershon S. Lithium plasma levels. *Psychopharm Bull*, 15(4):35-37, 1979.
298. Reisberg B, Gershon S. Side effects associated with lithium therapy. *Arch Gen Psychiatry*, 36(8): 879-87, 1979.
299. Angrist B, Rotrosen J, Gershon S. Assessment of dopaminergic function in schizophrenia. *Psychopharm Bull*, 16(1):59-60, 1980.
300. Angrist B, Rotrosen J, Gershon S. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. *Psychopharm*, 67(1):31-38, 1980.
301. Allikmets LH, Stanley M, Gershon S. The effect of lithium on chronic haloperidol enhanced apomorp aggression in rats. *Life Sci*, 25(2):165-170, 1979.
302. Hine B, Traficante LJ, Sakalis G, Gershon S. Thioridazine and EKG anomalies. *Experientia*, 35:1631, 1979.
304. Hine B, Sakalis G, Gershon S. Antagonism of amphetamine-induced stereotyped behavior in dogs by thioridazine and mesoridazine. *Res Comm in Psychology, Psychiat & Behav*, 4(1):89-92, 1979.

305. Stanley M, Russo A, Gershon S. The effect of MJ-9022-1 on striatal dopac and apomorp-induced stereotyped behavior in the rat. *Res Comm in Psychology Psychiat & Behav*, 4(2):127-134, 1979.
306. Stanley M, Rotrosen J, Sculerati N, Gershon S, Kuhn C, Cohen BM. Atypical antidopaminergic properties of CI-686: A potential antipsychotic agent. *Psychopharm*, 66(1):23-27, 1979.
307. Georgotas A, Serra MT, Green DE, Perel JM, Gershon S, Forrest IS. Chlorpromazine excretion. III. Fecal excretion of ¹⁴C-Chlorpromazine in chronically dosed patients. *Commun in Psychopharm*, 3(3):197-202, 1979.
308. Ferris SH, Sathananthan G, Reisberg B, Gershon S. Long-term choline treatment of memory-impaired elderly patients. *Science*, 205(4410):1039-40, 1979.
309. Lautin A, Stanley M, Angrist B, Gershon S. Extrapyramidal syndrome with sodium valproate. *Brit Med Journal*, 2(6197):1035-1036, 1979.
310. Gershon S. Status of psychopharmacology teaching and practice impact on health care delivery. Presented at symposium on Training in Psychopharmacology & Use of Psychotropic Drugs, The Royal Australian and New Zealand College of Psychiatrists, Singapore, 1978. *Psychopharm Bull*, 15(2):55-58, 1979.
311. Sakalis G, Gershon S. Parenteral loxapine in acute schizophrenia. *Curr Therap Res*, 25(2):330-334, 1979.
312. Kinon G, Sakalis G, Traficante LJ, Aronson M, Bowers P, Gershon S. Mesoridazine in treatment-refractory schizophrenics. *Curr Ther Res*, 25(4):534-539, 1979.
313. Annitto W, Gershon S. What's the "use"? A look at drug therapeutics and the "New" FDA regulations. *Trends in Neurosciences*, 2(7):1-11, 1979.
314. Stanley M, Lautin A, Rotrosen J, Gershon S. Antipsychotic efficacy of metaclopramide: Do DA/neuroleptic receptors mediate the action of antipsychotic drugs? *IRCS Medical Science*, 7:322, 1979.
315. deLeon MJ, Ferris SH, Blau I, George AE, Reisberg B, Krichell I, Gershon S. Correlations between computerized tomographic changes and behavioral deficits in senile dementia. (LETTER) *Lancet*, 2(8147):859-60, 1979.
316. Traficante L, Rotrosen J, Siekierski J, Gracer H, Gershon S. Purification and partial characterization of a human brain enzyme: Specificity for met-enkephalin. *IRCS Medical Science*, 7:561, 1979.
317. Mann J, Gershon S. Antidepressant properties of a selective monoamine oxidase inhibitor: L-deprenyl. *IRCS Medical Science*, 7:450, 1979.
318. Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M. Treatment of schizophrenia with sodium valproate. *IRCS Medical Science*, 7:569, 1979.
319. Stanley M, Rotrosen J, Lautin A, Wazer D, Gershon S. Tardive dyskinesia and metoclopramide (LETTER), *Lancet*, 2(8153):1190, 1979.
320. deLeon M, Ferris S, George A, Blau I, Kricheff II, Reisberg B, Gershon S. A new method for the CT evaluation of brain atrophy in senile dementia. *IRCS Medical Science*, 7:404, 1979.
321. Rotrosen J, Miller AD, Mandio D, Traficante LJ, Gershon S. Prostaglandins, platelets, and schizophrenia. *Arch Gen Psychiatry*, 37(9):1047-1054, 1980.

322. DeLeon MJ, Ferris SH, George AE, Reisberg B, Kricheff IJ, Gershon S. Computed tomography evaluations of brain-behavior relationships in senile dementia of the Alzheimer's type. *Neurobiology of Aging*, 1:69-79, 1980.
323. Georgotas A, Gershon S. Biology and pharmacological treatment of depression. *Hillside J of Clin Psychiat*, 2(1):27-39, 1980.
324. Gershon S, Newton R. Lack of anticholinergic side effects of a new antidepressant - Trazodone. *J Clin Psychiatry*, 41(3):100-104, 1980.
325. Lautin A, Angrist B, Stanley M, Gershon S, Heckl K, Karobath M. Sodium valproate in schizophrenia: Some biochemical correlates. *Brit J Psychiatry*, 137:240-244, 1980.
326. Lautin A, Wazer D, Stanley M, Rotrosen J, Gershon S. Chronic treatment with metoclopramide induces behavioral supersensitivity to apomorphine and enhances specific binding of 3H-spiroperidol to rat striata. *Life Sci*, 27(4):305-316, 1980.
327. Rotrosen J, Stanley M, Kuhn C, Waser D, Gershon S. Experimental dystonia induced by quaternary-chlorpromazine. *Neurology*, 30(8):878-881, 1980.
328. Stanley M, Lautin A, Rotrosen J, Gershon S, Kleinberg D. Metoclopramide: Antipsychotic efficacy of a drug lacking potency in receptor models. *Psychopharmacology*, 71(3):219-225, 1980.
329. Traficante LJ, Siekierski J, Rotrosen J, Gershon S. Antibiotics as inhibitors of enkephalin degradation by human brain. *Pharmacol Res Commun*, 12(6):575-580, 1980.
330. Rotrosen J, Mandio D, Segarnick D, Traficante LJ, Gershon S. Ethanol and prostaglandin E₁: Biochemical and behavioral interactions. *Life Sci*, 26(22):1867-1876, 1980.
331. Georgotas A, Bush D, Gershon S. Zimelidine vs. amitriptyline vs. placebo in a double-blind study. Recent advances in the treatment of depression. Proceedings of an International Symposium, Corfu, Greece, April 16-18, 1980. *Acta Psychiatr Scand*, 290(63)(Suppl.):256, 1981.
332. Georgotas A, Dunner DL, Meltzer HL, Solomon M, Fieve RR, Gershon S. The importance of dietary control in metabolic studies of manic-depressive patients. *Biol Psychiatry*, 15(1):157-163, 1980.
333. Mann J, Gershon S. L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. *Life Sci*, 26(11):877-82, 1980.
334. Traficante L, Rotrosen J, Siekierski J, Tracer H, Gershon S. Enkephalin inactivation by N-terminal tyrosine cleavage: Purification and partial characterization of a highly specific enzyme from human brain. *Life Sci*, 26:1697-1706, 1980.
335. Mann JJ, Stanley M, Gershon S, Rossor M. Mental symptoms in Huntington's disease and a possible primary aminergic neuron lesion. *Science*, 210(4476):1369-1371, 1980.
336. Mann J, Peselow ED, Snyderman S, Gershon S. D-phenylalanine in endogenous depression. *Am J Psychiatry*, 137(12):1611-1612, 1980.
337. Georgotas A, Fiegelson E, Gershon S. Catatonia: Highlights of the World Literature. *The Hillside J of Clinical Psychiatry*, 2(2):131-155, 1980.
338. Angrist B, Rotrosen J, Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. *Psychopharmacology*, 72(1):17-19, 1980.

339. Georgotas A, Mann J, Bush D, Gershon S. A clinical trial of zimelidine in depression. *Commun in Psychopharm*, 4:71-77, 1980.
340. Mann J, Friedman E, Georgotas A, Gershon S. The antidepressant effect of trazodone and inhibition of platelet serotonin reuptake. *Comm in Psychopharm*, 4:293-301, 1980.
341. Mann J, Peselow ED, Collora M, Gershon S. D-phenylalanine in the treatment of endogenous depression. *IRCS Medical Science*, 8:116, 1980.
342. Gershon S, Crook T, Ferris S, Reisberg B. Psychostimulants and neuropeptides in gero-psychiatry. *Psychopharm Bull*, 16(4):31-34, 1980.
343. Hardesty A, Burdock E, Gershon S. Selection of subjects for drug trials. *Psychopharm Bull*, 16(2):39-43, 1980.
344. Gershon S. Psychopharmacology of neurotransmitter systems in aging. *Psychopharm Bull*, 16(2):76-77, 1980.
345. Peselow E, Gershon S. Update on depression. *Resident & Staff Physician*, Nov.:82-100, 1980.
346. Gershon S. Introduction: Depression today and tomorrow. Proceedings of the symposium Progress in the Pharmacotherapy of Depression held in conjunction with Annual Meeting of the American Psychiatric Association, San Francisco, May, 1980. *Psychiatric Annals*, 10(9):S2, 1980.
347. Mann J, Friedman E, Georgotas A, Gershon S. Platelet serotonin uptake in endogenous depression before and after a selective serotonin uptake inhibitor. *Commun in Psychopharm*, 4:293-301, 1981.
348. Deutsch S, Traficante L, Gershon S, Peselow E, Rotrosen J. A rapid and sensitive dansylation-thin layer chromatographic method for the assay of free amino acid glycine in ultrafiltrates of plasma and RBC lysates. *Res Comm in Psychol, Psychiat, & Behav*, 6(3):193-204, 1981.
349. Freedman DX, Gershon S (Eds.). Pharmacology, efficacy and safety of a new antidepressant. *J of Clin Psychopharm*, 1(6)(1S-93S), 1981.
350. Georgotas A, Gerbino L, Jordan B, McCarthy M, Gershon S, Kleinberg D, Lautin A, Stanley M, Rotrosen J. A double-blind comparison of trebenzomine and thioridazine in the treatment of schizophrenia. *Psychopharmacology*, 73(3):292-4, 1981.
351. Deutsch SI, Peselow ED, Banay-Schwartz M, Gershon S, Virgilio J, Fieve RR, Rotrosen J. Effect of lithium on glycine levels in patients with affective disorders. *Am J Psychiat*, 138(5):683-4, 1981.
352. Gershon S, Mann J, Newton R, Gunther BJ. Evaluation of trazodone in the treatment of endogenous depression: Results of a multicenter double-blind study. *J of Clin Psychopharm*, 1(6):39S-44S, 1981.
353. Gershon S, Sakalis G, Bowers PA. Mesoridazine - a pharmacodynamic and pharmacokinetic profile. *J Clin Psychiatry*, 42(12):463-9, 1981.
354. Mann J, Georgotas A, Newton R, Gershon S. A controlled study of trazodone, imipramine and placebo in outpatients with endogenous depression. *J Clin Psychopharm*, 1(2):75-80, 1981.
355. Georgotas A, Gershon S. Historical perspectives and current highlights on lithium treatment in manic-depressive illness. *J Clin Psychopharm*, 1(1):27-31, 1981.

356. Gershon S. The study of behavior: Psychopharmacologic approaches. In: Career Directions, Sandoz Publ., 1980, 7(3):13-24.
357. Reisberg B, Ferris SH, Gershon S. An overview of pharmacologic treatment of cognitive decline in the aged. *Am J Psychiat*, 138(5):593-600, 1981.
358. Mann JJ, Stanley M, Neophytides A, deLeon MJ, Ferris SH, Gershon S. Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit. *Neurobiol Aging*, 2(1):57-60, 1981.
359. Mann JJ, Kaplan RD, Georgotas A, Friedman E, Branchey M, Gershon S. Monoamine oxidase activity and enzyme kinetics in three subpopulations of density-fractionated platelets in chronic paranoid schizophrenics. *Psychopharm*, 74(4):344-8, 1981.
360. Pomara N, Reisberg B, Albers S, Ferris S, Gershon S. Extrapyrmidal symptoms in patients with primary degenerative dementia. *J Clin Psychopharm*, 1(6):398-400, 1981.
361. Gershon S. The many faces of anxiety: Proceedings from a symposium. *J Clin Psychiat*, 42(2):11, 1981.
362. Pomara N, Gershon S. Psychopharmacotherapy: From the 1950's to the 1980's. *Psychosomatics*, 22(6):526-30, 1981.
363. Georgotas A, Mann J, Bush D, Gershon S. Safety data on zimelidine hydrochloride following an overdose. *Acta Psychiatr Scand*, 290(Suppl.):257-61, 1981.
364. Reisberg B, Ferris S, Schneck M, deLeon M, Crook T, Gershon S. The relationship between psychiatric assessments and cognitive test measures in mild to moderately cognitively impaired elderly. *Psychopharm Bull*, 17(1):99-101, 1981.
365. Gershon S, Goodnick P. Lithium use in affective disorders. *Psychiat Annals*, 11:143-153, 1981.
366. Gershon S. Neuroleptic-induced psychotic deterioration in a schizophrenic. (Letter to the Editor), *J Clin Psychopharm*, 1(2):96, 1981.
367. Georgotas A, Gershon S. The specificity of lithium. *Br J Psychiat*, July:139-83, 1981.
368. Gershon S. The conduct of clinical trials in the impaired elderly. *Psychopharm Bull*, 17(4):108-16, 1981.
369. Pohl R, Gershon S. Nomifensine: A new antidepressant. *Psychiat Annals*, 11(11):391-395, 1981.
370. Gershon S. Current research in depression. II. Clinical aspects discussion. *Acta Psychiatr Scand*, 290:257-61, 1981.
371. Rotrosen J, Stanley M, Lautin A, Wazer D, Gershon S. Discrimination of functionally heterogeneous receptor subpopulations: Antipsychotic and antidopaminergic properties of metoclopramide. *Psychopharm Bull*, 17(1):110-3, 1981.
372. Gershon S, Herman SP. The differential diagnosis of dementia. *J Am Geriatr Soc*, 30(11):S58-66, 1982.
373. Georgotas A, Forsell TL, Mann JJ, Kim M, Gershon S. Trazadone-hydrochloride: A wide spectrum antidepressant with a unique pharmacological profile. (A review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology). *Pharmacotherapy*, 2(5):255-265, 1982.
374. Kaufman M, Kahaner K, Peselow ED, Gershon S. Steroid psychoses: Case report and brief overview. *J Clin Psych*, 43(2):75-76, 1982.

375. Stanley M, Virgilio J, Gershon S. Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. *Science*, 216(4552):1337-1339, 1982.
376. Mann JJ, Frances A, Kaplan RD, Kocsis J, Peselow ED, Gershon S. The relative efficacy of L-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. *J Clin Psychopharm*, 2(1):54-57, 1982.
377. Gershon S. Edited Volume - Cardiovascular effects of psychotropic drugs. *J of Clin Psych*, 43(5)(2)(Suppl.):1-43, 1982.
378. Georgotas A, Krakowski M, Gershon S. Controlled trial of zimelidine, a 5-HT reuptake inhibitor, for treatment of depression. *Am J Psychiatry*, 139(8):1057-8, 1982.
379. Gershon S. Drug interactions in controlled clinical trials. *J Clin Psychiatry*, 43(2):12, 1982.
380. Gershon S. Introduction. *J Clin Psychiatry*, 43:9(Sec. 2):3, 1982.
381. Gershon S. Cardiovascular effects of psychotropic drugs. (Proceedings of scientific session at the World Congress of Biological Psychiatry, June 28-July 3, 1981, Stockholm, Sweden). *J of Clin Psychia*, 43(5):4-43, 1982.
382. Mann JJ, Frances A, Peselow ED, Gershon S. Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendogenous depression. *Psychopharm Bull*, 18(4):182-184, 1982.
383. Gershon S. Problems with tricyclic antidepressant therapy. Scientific Exhibit, Mead Johnson, 1982.
384. Brinkman S, Pomara N, Domino E, Barnett N, Gershon S. Lithium, memory and RBC/plasma choline in Alzheimer-type dementia. *IRCS Medical Science*, 10:326-327, 1982.
385. Kelwala S, Stanley M, Gershon S. History of antidepressants: Successes and failures. *J Clin Psychia*, 44:5(Sec. 2):40-48, 1983.
386. Brinkman SD, Gershon S. Measurement of cholinergic drug effects on memory in Alzheimer's disease. *Neurobiology of Aging*, 4:139-145, 1983.
387. Lerer B, Stanley M, Demetriou S, Gershon S. Effect of electroconvulsive shock on muscarinic cholinergic receptors in rat cerebral cortex and hippocampus. *J of Neurochem*, 41(6):1680-1683, 1983.
388. Pomara N, Block R, Demetriou S, Fucek F, Stanley M, Gershon S. Attenuation of pilocarpine-induced hypothermia in response to chronic administration of choline. *Psychopharmacology*, 80:129-130, 1983.
389. Claghorn J, Gershon S, Goldstein BJ, Behrnetz S, Bush DG, Huitfeldt B. A double-blind evaluation of zimelidine in comparison to placebo and amitriptyline in patients with major depressive disorder. *Prog Neuro-Psychopharmacol & Biol Psychiatry*, 7:367-382, 1983.
390. Sitaram N, Jones D, Kelwala S, Bell J, Stevenson J, Gershon S. Pharmacology of the human iris: Development and use of challenge strategies in the study of antidepressant response. *Prog Neuro-Psychopharmacol & Biol Psychiat*, 7:273-286, 1983.
391. Sitaram N, Gershon S. From animals models to clinical testing - promises and pitfalls. *Prog Neuro-Psychopharmacol & Biol Psychiatry*, 7:227-228, 1983.
392. Gershon S, Eison AS. Anxiolytic profiles. *J Clin Psychiat*, 44:11(Sec. 2):45-46, 1983.

393. Claghorn J, Gershon S, Goldstein BJ. Zimeldine tolerability in comparison to amitriptyline and placebo: findings from a multicentre trial. *Acta Psychiatr Scand*, 68(308):104-114, 1983.
394. Oxenkrug GF, Pomara N, McIntyre IM, Branconnier RJ, Stanley M, Gershon S. Aging and cortisol resistance to suppression by dexamethasone: A positive correlation. *Psychiatry Research*, 10:125-130, 1983.
395. Pomara N, Banay-Schwartz M, Block R, Stanley M, Gershon S. Elevation of RBC glycine and choline levels in geriatric patients treated with lithium. *Am J Psychiatry*, 140(7):911-913, 1983.
396. Stanley M, Mann JJ, Gershon S. Alterations in pre- and post-synaptic serotonergic neurons in suicide victims. *Psychopharm Bull*, 19(4), 1983.
397. Pomara N, Block R, Abraham J, Domino EF, Gershon S. Combined cholinergic precursor treatment and dihydroergotoxine mesylate in Alzheimer's disease. *IRCS Med Sci*, 11:1048-1049, 1983.
398. Pohl R, Rainey JM Jr, Gershon S. Changes in the drug treatment of anxiety disorders. *Psychopathology*, 17(1):6-14, 1984.
399. Brinkman SD, Pomara N, Barnett N, Block R, Domino EF, Gershon S. Lithium-induced increases in red blood cell choline and memory performance in Alzheimer-type dementia. *Biological Psychiatry*, 19(2):157-164, 1984.
400. Kelwala S, Pomara N, Stanley M, Sitaram N, Gershon S. Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer's disease. *J Clin Psychiat*, 45(8):342-344, 1984.
401. Gershon S. Comparative side effect profiles of Trazodone and Imipramine: Special reference to the geriatric population. *Psychopathology*, 17(2):39-50, 1984.
402. McIntyre IM, Oxenkrug GF, Stanley M, Gershon S. The effect of 5,7-dihydroxytryptamine on the serum corticosterone resistance to suppression by dexamethasone. *Brain Research*, 309:156-158, 1984.
403. Oxenkrug GF, McIntyre IM, Stanley M, Gershon S. Dexamethasone suppression test: Experimental model in rats and effect of age. *Biological Psychiatry*, 19(3):413-416, 1984.
404. Pomara N, Coffman KL, Bush DF, Gershon S. Myalgia and elevation in muscle creatine phosphokinase during zimelidine treatment. *J Clin Psychopharm*, 4(4):220-222, 1984.
405. Oxenkrug GF, McIntyre IM, Gershon S. Effects of pinealectomy and aging on the serum corticosterone circadian rhythm in rats. *J of Pineal Research*, 1:181-185, 1984.
406. Pomara N, Stanley B, Block R, Guido J, Russ D, Berchou R, Stanley M, Greenblatt DJ, Newton RE, Gershon S. Adverse effects of single therapeutic doses of diazepam on performance in normal geriatric subjects: Relationship to plasma concentrations. *Psychopharmacology*, 84:342-346, 1984.
407. Branconnier RJ, Oxenkrug GF, McIntyre IM, Pomara N, Harto NE, Gershon S. Prediction of serum cortisol response to dexamethasone in normal volunteers: A multivariate approach. *Psychopharmacology*, 84:274, 1984.

408. Pomara N, Oxenkrug GF, McIntyre IM, Block R, Stanley M, Gershon S. Does severity of dementia modulate response to dexamethasone in individuals with primary degenerative dementia? *Biol Psychiatry*, 19(10):1481-1487, 1984.
409. Hryhorczuk LM, Novak EA, Gershon S. Gut flora and urinary phenylacetic acid. *Science*, 226:996, 1984.
410. Pomara N, Gershon S. Treatment-resistant depression in an elderly patient with pancreatic carcinoma: Case report. *J Clinical Psychiatry*, 45(10):439-440, 1984.
411. Goodnick P, Gershon S. Chemotherapy of cognitive disorders in geriatric subjects. *J Clin Psychiatry*, 45(5):197-209, 1984.
412. Pomara N, Stanley B, Block R, Guido J, Stanley M, Greenblatt DJ, Newton RE, Gershon S. Diazepam impairs performance in normal elderly subjects. *Psychopharm Bull*, 20(1):137-139, 1984.
413. Gershon S. The psychopharmacology evolution in psychiatry. *Curr Clin Briefs*, 3-5, 1984.
414. Gershon S. Introduction to sociological and physiological considerations associated with anxiolytic therapy. *Family Practice Recertification*, 6(10):7-10, 1984.
415. Pomara N, Block R, Moore N, Rhiew HB, Berchou R, Stanley M, Gershon S. Combined piracetam and cholinergic precursor treatment for primary degenerative dementia. *IRCS Med Sci*, 12:338-389, 1984.
416. Pomara N, Block R, Domino EF, Gershon S. Decay in plasma lithium and normalization in red blood cell choline following cessation of lithium treatment in two elderly individuals with Alzheimer-type dementia. *Biol Psychiat*, 19(6):919-922, 1984.
417. Heninger GR, Forrest JN, Cox M, Stokes PE, Gershon S, Cowdry R. Long-term effects of lithium on the kidney. *Clinical Neuropharmacology*, 7(1):864-865, 1984.
418. Gershon S (Moderator). Synopsis - Psychopharmacology for the Primary Care Physician. A symposium held following the Annual Meeting of the American Academy of Family Physicians, Miami, October, 1983. 1984 June.
419. Chayasirisobhon S, Brinkman SD, Gerganoff S, Gershon S, Pomara N, Green V. Event-related potential in Alzheimer's disease. *Clinical Electroencephalography*, 16(1):48-52, 1985.
420. Gershon S, McIntyre IM, Pomara N, Stanley M, Oxenkrug G. Alterations in cholinergic receptors mediate the effects of dexamethasone on corticosterone. *Biol Psychiatry*, 20:458-460, 1985.
421. Moore NC, Lerer B, Meyendorff E, Gershon S. Three cases of carbamazepine toxicity. *Am J Psychiatry*, 142(8):974-975, 1985.
422. McIntyre IM, Gershon S. Interpatient variations in antipsychotic therapy. *J Clin Psychiatry*, 46(5)(2):3-5, 1985.
423. Pomara N, Robert R, Rhiew B, Stanley M, Gershon S. Multiple, single-dose Naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer's disease. *Neurobiology of Aging*, 6:233-236, 1985.
424. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S. Carbamazepine and lithium: Different profiles in affective disorder? *Psychopharm Bull*, 21(1):18-22, 1985.

425. Gershon S (Chairman), Richelson E, Goldberg HL, Rakel RE, Kallman H, Flomenbaum N. Desyrel (Trazodone HCl) a compendium of three years of clinical use. Proceedings of a symposium held September 14, 1984, Chicago, Illinois.
426. Bannon JA, Eisold JF, Faich GA, Gaffney TE, Gershon S, Grabowski HG, Harrison DG, Helms RB, Jick H, Moss AJ, Shnider BI, Freedman DX, Lasagna L, Levine RJ, Sonnenreich MR. Post-Approval Pharmaceutical Research and Development, Report - Prepared by Medicine in the Public Interest, Inc. (MIPI) Copyright 1985.
427. Gershon S. Chronic pain: hypothesized mechanism and rationale for treatment. *Neuropsychobiology*, 15(1):22-27, 1986.
428. Gershon S, Yeragani VK, Aleem A. Tolerance et pharmacovigilance de la trazodone. *L'Encephale*, XII:249-57, 1986.
429. Ortiz A, Gershon S. The future of neuroleptic psychopharmacology. *J Clin Psychiatry*, 47(5):3-11, 1986.
430. Pohl R, Yeragani V, Ortiz A, Rainey J, Gershon S. Response of tricyclic-induced jitteriness to a phenothiazine: Two case reports. *J Clin Psych*, 47:427, 1986.
431. Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S. Age-associated memory impairment: Proposed diagnostic criteria and measures of clinical change - report of a National Institute of Mental Health work group. *Develop Neuropsych*, 2(4):261-276, 1986.
432. Yeragani, V.K., Gershon, S.: Hammond and Lithium: Historical update. In: *Biological Psychiatry*, 21:1101-1109, 1986.
433. Lerer B, Moore N, Meyendorff E, Cho S-R, Gershon S. Carbamazepine versus lithium in mania: A double-blind study. *J Clin Psychiatry*, 48:89-93, 1987.
434. Jain AK, Kelwala S, Gershon S. Antipsychotic drugs: Current issues and future directions. *Int Clin Psychopharm*, 3:1-32, 1988.
435. Moore N, Meyendorff E, Yeragani V, LeWitt P, Gershon S. Tiaspirone in schizophrenia. *J Clin Psychopharmacol*, 7(2):98-101, 1987.
436. Yeragani V, Pohl R, Rainey J, Balon R, Ortiz A, Lycaki H, Gershon S. Pre-infusion heart rates and laboratory induced panic anxiety. *Acta Psychiat Scand*, 75:51-54, 1987.
437. Ortiz A, Gershon S. Plasma levels of neuroleptics in clinical treatment of acute psychotic states. *ISI Atlas of Science*, 60-62, 1987.
438. Gershon S, Eison A. The ideal anxiolytic. *Psychiatric Annals*, 17(3):156-170, 1987.
439. Yeragani V, Pohl R, Keshavan M, Gershon S. Are tricyclic antidepressants effective for aphthous ulcers? *J Clin Psychiat*, 48:256, 1987.
440. Yeragani V, Aleem A, Pohl R, Gershon S. Neuropharmacological basis of priapism. *Clin Neuropharm*, 10(2):93-95, 1987.
441. Jain AK, Kelwala S, Moore N, Gershon S. A controlled clinical trial of tiaspirone in schizophrenia. *Int Clin Psychopharm*, 2:129-133, 1987.
442. Jain AK, Kelwala S, Gershon S. Antipsychotic drugs in schizophrenia: Current issues. *Int Clin Psychopharm*, 3(1):1-30, 1988.

443. Ortiz A, Pohl R, Gershon S. Azaspirodecanediones in generalized anxiety disorder: Buspirone. *J Affec Dis*, 13(2):131-143, 1987.
444. Jones D, Gershon S, Sitaram N, Keshavan M. Sleep and depression. *Psychopathology*, 20(Suppl. 1):20-31, 1987.
445. Yeragani VK, Gershon S. Priapism related to phenelzine therapy. *New Eng J Med*, (letter), July 9, 1987.
446. Yeragani VK, Pohl R, Balon R, Gershon S. Migraine and panic disorder. *J Clin Psychopharm*, 8(2):148, April 1988.
447. Yeragani VK, Rainey JM, Pohl R, Ortiz A, Weinberg P, Gershon S. Thyroid hormone levels in panic disorder. *Can J Psychiat*, 32:467-469, 1987.
448. Moore NC, LeWitt PAL, Galloway MP, Gershon S. Which atypical antipsychotics are identified by screening tests? *Clinical Neuropharmacology*, 12(3):167-184, 1989.
449. Gershon S. Taking issue: Antipsychotic agents of the future. *Hospital and Community Psychiatry*, 38(11):1141, 1987. (Letter).
450. Balon R, Yeragani VK, Pohl RB, Gershon S. Lithium discontinuation: withdrawal or relapse? *Comprehensive Psychiatry*, 29(3):330-334, 1988.
451. Pohl R, Balon R, Yeragani VK, Gershon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. *Psychopathology*, 22(Suppl. 1):60-67, 1989.
452. Rosen J, Bohon S, Gershon S. Antipsychotics in the elderly. *Acta Psychiatrica Scandinavica*, 82(Suppl 358):170-175, 1990.
453. Moore NC, LeWitt PA, Gershon S. Reduction of dyskinesias and psychiatric disability with clozapine: Different time courses. *J Psychopharmacology*, 6(4):514-518, 1992.
454. Oxenkrug GF, Gurevich D, Siegel B, Dumlao MS, Gershon S. Correlation between brain-adrenal axis activation and cognitive impairment in Alzheimer's disease: is there a gender effect? *Psychiatry Research*, 29:169-175, 1989.
455. Kabins D, Gershon S. Beyond Tricyclics -- New approaches to depression: potential applications for MAO-B inhibitors. *Dementia*, 1:323-348, 1990.
456. Wright B, Rosenberg D, Gershon S. Cognitive enhancing agents for the treatment of senile dementia of the Alzheimer's type. *Drugs of Today*, 26(7):449-471, 1990.
457. Vogel-Scibilia S, Gershon S. An update on cognition enhancers for the elderly. *New Trends in Clinical Neuropharmacology*, 3(4):207-216, 1989. Presented at the Conference on Mental Decline of Elderly People, Rome, November 23-25, 1989.
458. Palmer AM, Gershon S. FJ-R-90-0033: Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? *FASEB Journal*, 4:2745-2752, 1990.
459. Clark DB, Friedman ES, Gershon S. Beyond tricyclics: Antidepressant medication in the 1990's. *Integrative Psychiatry*, 8(1):2-18, 1992.
460. Gershon S, Wright B, Rosenberg D. Potential treatment modalities for senile dementia of the Alzheimer's type. *Neurology Forum*, 1(3):2-7, 1990.

461. Moore NC, Gershon S. The brain renin-angiotensin system and behavior. *Dementia*, 1(4):225-236, 1990.
462. Friedman ES, Clark DB, Gershon S. Stress, anxiety, and depression: A review. *Journal of Anxiety Disorders*, 6:337-363, 1992.
463. Rosenberg D, Wright B, Gershon S. Depression in the elderly. *Dementia*, 3:157-173, 1992.
464. Gershon S. Introduction: insights in the use of trazodone in depressed patients. *J Clin Psychiatry*, September, 1990 supplement. pp. 4-5. Presented at that the World Congress of Psychiatry Meeting in Athens, Greece, October, 1989.
465. Diehl D, Gershon S. The role of dopamine in mood disorders. *Comprehensive Psychiatry*, 33(2):115-120, 1992.
466. Brown A, Gershon S. Dopamine and depression. *J Neural Transmission*, 91:75-109, 1993.
467. Holttum J, Gershon S. Cholinergic agents in dementia, Alzheimer's type. *Dementia*, 3:174-185, 1992.
468. Tuma H, Stricker E, Gershon S. Advances in neuroscience and schizophrenia. *J Neural Transmission*, Supplement 36, 1992.
469. Mulsant B, Gershon S. Neuroleptics in the treatment of psychosis in late life: A rational approach. *International Journal of Geriatric Psychiatry*, 8:979-992, 1993.
470. Gershon S. Depression: Patient profile and treatment options confront issues with the experts. *J Clin Psych*, 52(10):437-439, 1991.
471. Gershon S. Concluding summary. Presented at that the First International Meeting on the Neuroleptic-Induced Deficit Syndrome, Paris, May 6-7, 1993, M. Lader & T. Lewander, Editors. *Acta Psychiatrica Scandinavica*, 89 (Suppl 380):83-85, 1994.
472. Soares JC, Gershon S. Advances in the pharmacotherapy of Alzheimer's disease. *Eur Arch Psych Clin Neurosci*, 244(5):261-271, 1994.
473. Soares JC, Gershon S. THA - historical aspects, review of pharmacological properties and therapeutic effects. *Dementia*, 6:225-234, 1995.
474. Detre T, Gershon S. Specificity and effectiveness of psychotropic agents. *Leadership Medica*, 196;12:4-15, 1996.
475. Soares JC, Gershon S. The lithium ion: A foundation for psychopharmacological specificity. *Neuropsychopharmacol*, 19:167-182, 1998.
476. Antelman SM, Soares JC, Gershon S. Time-dependent sensitization - Possible implications for clinical psychopharmacology. *Behav Pharmacol*, 8:505-514, 1997.
477. Soares JC, Gershon S. Prospects for the development of new treatments with a rapid onset of action in affective disorders. *Drugs*, 52(4):477-482, 1996.
478. Gershon S, Soares JC. Current therapeutic profile of lithium. *Arch Gen Psychiatry*, 54:16-20, 1997.

479. Antelman SM, Caggiula AR, Kucinski BJ, Fowler H, Gershon S, Edwards DJ, Austin MC, Stiller R, Kiss S, Kocan D. The effects of lithium on a potential cycling model of bipolar disorder. *Prog Neuropsychopharmacol & Biol Psychiatry*, 22:495-510, 1998.
480. Rosenberg DR, Gershon S. Developmental constructs in neuropsychiatric research. *Dev Brain Dysfunct*, 10:96-117;1997.
481. Soares JC, Mallinger AG, Gershon S. The role of antipsychotic agents in the treatment of bipolar disorder patients. *Int Clin Psychopharmacol*, 12:65-76,1997.
482. Antelman SM, Caggiula AR, Gershon S, Edwards DJ, Austin MC, Kiss S, Kocan D. Stressor-induced oscillation: A possible model of the bidirectional symptoms in PTSD. *Ann N Y Acad Sci*, 8(21):296-304, 1997.
483. Soares JC, Gershon S. Therapeutic targets in late life psychosis: Review of concepts and critical issues. *Schiz Res*, 27:227-239, 1997.
484. Caggiula AR, Antelman SM, Kucinski BJ, Fowler H, Edwards DJ, Austin MC, Gershon S, Stiller R. Oscillatory-sensitization model of repeated drug exposure: Cocaine's effects on shock-induced hypoalgesia. *Prog Neuropsychopharmacol & Biol Psychiatry*, 22:511-521, 1998.
485. Kucinski BJ, Antelman SM, Caggiula AR, Fowler H, Gershon S, Edwards DJ, Austin MC. Oscillatory effects of repeated morphine on shock-induced hypoalgesia in β -endorphin. *Synapse*, 30:30-37, 1998.
486. Soares JC, Antelman SM, Gershon S. The relevance of time-dependent sensitization (TDS) to the mechanism of action of antidepressant medications. Submitted for publication in the *7th IMCPP Proceedings*, Spain, 1997
487. Antelman SM, Gershon S. Clinical application of time-dependent sensitization to antidepressant therapy. *Prog Neuropsychopharmacol & Biol Psychiatry*, 22:65-78, 1998.
488. Levine J, Cole DP, Chengappa KN, Gershon S. Anxiety disorders and major depression, together or apart.. *Depress Anxiety*, 14:94-104, 2001.
489. Pettegrew JW, Panchalingam K, Levine J, McClure RJ, Gershon S, Yao JK. Chronic *myo*-inositol increases rat brain phosphatidylethanolamine plasmalogen. *Biol Psychiatry*, 49:444-453, 2001.
490. Soares JC, Gershon S. Introductory editorial for bipolar disorders -- An international journal of psychiatry and neurosciences. *Bipolar Disorders*, 1:1-2, 1999.
491. Chengappa KN, Levine J, Gershon A, Mallinger AG, Hardan A, Vagnucci A, Pollock B, Luther J, Battenfield J, Verfaillie S, Kupfer DJ. Inositol as an add-on treatment for bipolar depression. *Bipolar Disorders*, 2:47-55, 2000.
492. Antelman SM, Caggiula AR, Edwards DJ, Gershon S, Kucinski BJ, Kiss S, Kocan D. Long-term oscillation of corticosterone following intermittent cocaine. *J Neural Transm*, 107:369-375, 2000.
493. Antelman SM, Levine J, Gershon S, Caggiula AR. Pills or placebos? *Science*, 7:913-914,1999.
494. Johnson G, Gershon S. Early North American research on lithium. *Aust N Z J Psychiatry*, 33:S48-53, 1999.
495. Kucinski BJ, Antelman SM, Caggiula AR, Fowler H, Gershon S, Edwards DJ. Cocaine-induced oscillation is conditionable. *Pharmacol Biochem Behav*, 63:449-455, 1999.

496. Levine J, Chengappa KNR, Brar JS, Gershon S, Yablonsky E, Stapf D, Kupfer DJ. Psychotropic drug prescription patterns among patients with bipolar I disorder. *Bipolar Disorders*, 2:120-130, 2000.
497. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW. Increased cerebrospinal fluid glutamine levels in depressed patients. *Biol Psychiatry*, 1;47:586-593, 2000.
498. Soares JC, Boada F, Spencer S, Mallinger AG, Dipoloid CS, Wells KF, Frank E, Keshavan MS, Gershon S, Kupfer DJ. Brain Lithium Concentrations in Bipolar Disorder Patients: Preliminary ⁷Li MRS Studies with 3T. *Biol Psychiatry*, 49:437-443, 2001.
499. Chengappa KN, Levine J, Gershon S, Kupfer DJ. Life-time prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders in a voluntary registry. *Bipolar Disorders*, 2, part 1:191-195, 2000.
500. Soares JC, Gershon S. The diagnostic boundaries of bipolar disorder. *Bipolar Disorders*, 2:1-2, 2000.
501. Soares JC, Gershon S. The psychopharmacologic specificity of the lithium ion: origins and trajectory. *J Clin Psychiatry*, 61:16-22, 2000.
502. Himmelhoch J, Levine J., Gershon S. Historical overview of the relationship between anxiety disorders and affective disorders. *Depress Anxiety* 14: 53-66, 2001.
503. Levine J, Chengappa KRN, Gershon S, Drevets W. Differentiating primary pathophysiologic from secondary adaptational processes. *Depress Anxiety* 14:105-11, 2001.
504. Levine J, Panchalingam K, McClure RJ, Gershon S, Pettegrew JW. Stability of CSF metabolites measured by proton NMR. *J Neural Transm*, 107: 843-848, 2000.
505. Antelman SM, Levine J, Gershon S. Time-dependent sensitization: the odyssey of a scientific heresy from the laboratory to the door of the clinic. *Mol Psychiatry*, July;5(4):350-6, 2000.
506. Levine J, Chengappa KNR, Brar JS, Gershon S, Kupfer D. Illness characteristics and their association with prescription patterns for bipolar I disorder. *Bipolar Disorders*, 3:41-49, 2001.
507. Pettegrew JW, Panchalingam K, McClure, Gershon S, Muenz LR, Levine J. Effects of chronic lithium administration on rat brain phosphatidylinositol cycle constituents, membrane phospholipids and amino acids. *Bipolar Disorders*, 3:189-201, 2001.
508. Pettegrew JW, Levine J, Gershon S, Stanley JA, Servan-Schreiber D, Panchalingam K, McClure, RJ. P-MRS study of Acetyl-L-Carnitine Treatment in Geriatric Depression: Preliminary Results. *Bipolar Disorders*, 4: 61-66, 2002.
509. Cornelius JR, Bukstein OG, Birmaher B, Salloum IM, Lynch K, Pollock NK, Gershon S, Clark D. Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial. *Addict Behav*, 26:735-739, 2001.
510. Chengappa KN, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. *Bipolar Disorders*, 3:215-232, 2001.
511. Angrist B, Rotrosen J, Gershon S. Commentary on: "Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia." *Psychopharmacology*, 158:219-221, 2001.
512. Levine J, Cole DP, Chengappa NR, Gershon S. Anxiety disorders and major depression, together or apart. *Depress Anxiety*, 14:94-104, 2001.

513. Chengappa KN, Baker RW, Shao L, Yatham LN, Tohen M, Gershon S, Kupfer DJ. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. *Bipolar Disorders*, 5(1):1-5, 2003.
514. Levine J, Panchalingam K, McClure RJ, Gershon S, Pettegrew JW. Effects of acetyl-L-carnitine and myo-inositol on high-energy phosphate and membrane phospholipid metabolism in zebra fish: a ³¹P-NMR-spectroscopy study. *Neurochem Res*, 28(5):687-90, 2003.
515. Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, Schlicht P, Kupfer DJ. The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype. *Bipolar Disord*, 6(4):314-8, 2004.
516. Buriakovsky I, Cohen H, Gershon S, Kaplan Z, Levine J, McClure R, Pettegrew J. Effect of intraperitoneal acetyl-L-carnitine (ALCAR) on anxiety-like behaviours in rats. *International Journal of Neuropsychopharmacology*, 8:65-74, 2005.
517. Chengappa KN, Hennen J, Baldessarini RJ, Kupfer DJ, Yatham LN, Gershon S, Baker RW, Tohen M. Recovery and functional outcomes following olanzapine treatment for bipolar I mania. *Bipolar Disord*, 7(1):68-76, 2005.
518. Chengappa K, Kupfer DJ, Parepally H, John V, Basu R, Battenfield J, Schlicht P, Houck P, Brar JS, Gershon S. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder — bipolar type. *Bipolar Disord*, 9(6):609-17, 2007.

(See additional citations from 2008 to present)

Books

1. Gershon S, Shopsin B. (Eds.) Lithium: Its Role in Psychiatric Research and Treatment. Plenum Press, New York, 1973.
2. Gershon S, Shopsin B. (Eds.) Amines and Affective State. (Journal of Nervous and Mental Disease, Suppl.) Williams & Wilkins, Co., Baltimore, 1974.
3. Sudilovsky A, Gershon S, Beer B. (Eds.) Predictability in Psychopharmacology: Preclinical and Clinical Correlations. Raven Press, New York, 1975.
4. Gershon S, Raskin A. (Eds.) Genesis and Treatment of Psychological Disorders in the Elderly. Aging Series, Volume 2. Raven Press, New York, 1975.
5. Terry R, Gershon S. (Eds.) Neurobiology of Aging. Aging Series, Volume 3. Raven Press, New York, 1976.
6. Shagass C, Gershon S. (Eds.) Psychopathology and Brain Dysfunction. Raven Press, New York, 1977.
7. Cooper T, Gershon S, Klein NS, Shou M. (Eds.) Lithium: Controversies and Unresolved Issues. International Congress Series, Volume 478. Elsevier/North Holland Biomedical Press, Amsterdam, 1980.
8. Gershon S. (Ed.) New Directions in Antidepressant Therapy. Royal Society of Medicine International Congress & Symposia Series, No. 46. Grune & Stratton, Inc., New York, 1981.

9. Crook T, Gershon S. (Eds.) Strategies for the Development of an Effective Treatment Senile Dementia. M.P.A., Inc., 1981.
10. Burdock EI, Sudilovsky A, Gershon S. (Eds.) Behavior of Psychiatric Patients: Quantitative Techniques for Evaluation. Marcel Dekker, Inc., New York, 1982.
11. Samuel D, Algeri S, Gershon S, Grimm V, Toffano G. Aging of the Brain. Aging Series, Volume 22. Raven Press, New York, 1983.
12. Crook T, Bartus R, Ferris S, Gershon S. (Eds.) Treatment Development Strategies for Alzheimer's Disease. M.P.A., Inc., 1986.
13. Gershon S. Booklet: Depression: An Ancient and Ubiquitous Disease. Multiclinic study of a novel antidepressant. A Scientific Exhibit, 1980.
14. Lerer B, Gershon S. (Eds.) New Directions in Affective Disorders. Springer Verlag, New York, 1989.
15. Gershon S, Pohl R. (Eds.) Progress in Basic and Clinical Pharmacology, Volume 3: Biological Basis of Psychiatric Treatment. Farmington, CT: Karger, 1990.
16. Crook T, Gershon S. (Eds.) Diagnosis and Treatment of Adult-Onset Cognitive Disorders. Old Saybrook, CT: Psymark Communications, Inc., 1991.
17. Rosenberg DR, Holttum JR, Gershon S. Textbook of Pharmacotherapy for Child and Adolescent Psychiatric Disorders. New York: Brunner/Mazel, 1994.
18. Richards S, Musser W, Gershon S. Maintenance Pharmacotherapy for Neuropsychiatric Disorders. Brunner/Mazel, Inc., New York, NY. 1998.
19. Rosenberg DR, Holttum J, Ryan N, Gershon S. Pocket Guide for the Textbook of Pharmacotherapy for Child and Adolescent Psychiatric Disorders. New York: Brunner/Mazel. 1997
20. Soares JC, Gershon S. Basic Mechanisms and Therapeutic Implications of Bipolar Disorders. Marcel Dekker, Inc. New York, NY. 1999.
21. Soares JC, Gershon S. Eds. Bipolar Disorders. Marcel Dekker, Inc.. New York, NY. 2000.
22. Rosenberg DR, Davanzo PA, Gershon S. (Eds.) Pharmacotherapy for Child and Adolescent Psychiatric Disorders, 2nd Edition. Marcel Dekker, Inc. New York, NY. 2002
23. Soares JC, Gershon S. Handbook of Medical Psychiatry. Marcel Dekker, Inc. New York, NY. 2003.
24. Rosenberg DR, Gershon S. (Eds.) Pharmacotherapy for Child and Adolescent Psychiatric Disorders, 3rd Edition. Wiley – Blackwell, Hoboken, New Jersey. 2012

Book Chapters and Invited Papers

1. Gershon S. A Physiological and Pharmacological Study of Succinate and Lithium Salt (with special reference to uses in clinical and experimental psychiatry). Melbourne University Press, Melbourne, Australia, 450, 1957.
2. Yaryura-Tobias JA, Neziroglu FA (Eds.), van Pragg HM (Series Ed.), Lader MH, Lipton M, Gershon S, Prange HJ, Jr. (Associate Eds.) Obsessive-Compulsive Disorders: Pathogenesis-Diagnosis-Treatment. Volume 8. Marcell Dekker, Inc., New York, 1983.

3. Angrist B, Gershon S. Amphetamine induced schizophreniform psychosis. In: Schizophrenia, Current Concepts and Research edited by Siva Sankar, PJD Publications, Hicksville, NY, 1969, pp. 508-524.
4. Gershon S. Predictiveness in psychopharmacology - Preclinical-clinical correlations. In: Psychopharmacology and the Individual Patient, edited by J.R. Wittenborn and S.C. Goldberg, Raven Press, New York, 1970.
5. Alpert M, Angrist B, Diamond F, Gershon S. Comparison of Ditrin intoxication and acute alcohol psychoses. In: Origins and Mechanisms of Hallucinations, edited by W. Keup, Plenum Press, 1970, pp. 245-259.
6. Gershon S. Methodology for drug evaluation in affective disorder: Mania. In: Principles and Problems of Establishing the Efficacy of Psychotropic Agents, U.S. Department of Health, Education and Welfare-Public Health Service, Health Services and Mental Health Administration- Washington, DC: National Institute of Mental Health, 1971, pp. 123-136.
7. Shopsin B, Gershon S. Chemotherapy of manic-depressive disorder. In: Brain Chemistry and Mental Disease, edited by B.T. Ho and W.M. Mclsaac, Plenum Pub. Corp., New York, 1971, pp. 319-377.
8. Angrist B, Gershon S. Possible dose-response relationships in amphetamine psychosis. In: Drug Abuse - Proceedings of the International Conference, edited by Chris J.D. Zarafonitis. Lea and Febiger, Pennsylvania 1972, pp. 263-269.
9. Angrist B, Gershon S. Psychiatric sequelae of amphetamine use. In: Psychiatric Complications of Medical Drugs, edited by R.I. Shader, Raven Press, New York, 1972, pp. 175-195.
10. Gershon S, Wallach M. Psychiatric sequelae to tuberculosis chemotherapy. In: Psychiatric Complications of Medical Drugs, edited by R.I. Shader, Raven Press, New York, 1972, pp. 201-212.
11. Gershon S. Some recent studies on amphetamine psychosis - Unresolved issues. In: Current Concepts in Amphetamine Abuse, edited by E.H. Elinwood and S. Cohen. Department of Health, Education and Welfare Publ. No. 72-90, 9085, 1972, pp. 193-204.
12. Angrist B, Gershon S. Amphetamine-induced psychosis. A possible approach to assessing pathogenic mechanisms in amphetamine psychosis. In: Proceedings, V World Congress of Psychiatry, edited by R. de la Fuente and M.N. Weisman, Excerpta Medica, Amsterdam, 1973.
13. Gershon S. Psychopharmacology of the aging patient: Anti-anxiety agents. In: Psychopharmacology and Aging, edited by Fann and Eisdorfer, Plenum Press, New York, 1973, pp. 183-187.
14. Angrist B, Gershon S. Effects of alterations of cholinergic function on behavior. In: Psychopathology and Psychopharmacology, edited by J.O. Cole, A.M. Freedman and A. Friedhoff, John Hopkins, Baltimore, 1973, pp. 15-36.
15. Angrist BM, Sathananthan G, Wilk S, Gershon S. Behavioral and biochemical effects of L-dopa in psychiatric patients. In: Frontiers in Catecholamine Research, edited by E. Usdin and S.H. Snyder, Pergamon Press, London, 1973, pp. 991-994.
16. Shopsin B, Wilk S, Gershon S, Roffman M, Goldstein M. Collaborative psychopharmacologic studies exploring catecholamine metabolism in psychiatric disorders. In: Frontiers in Catecholamine Research, edited by E. Usdin and S.H. Snyder, Pergamon Press, London, 1973, pp. 1173-1179.

17. Chan TL, Gershon S. Quantitation of chlorpromazine and its metabolites in human plasma and urine by thin-layer chromatography. In: Quantitative Thin-Layer Chromatography, ed. by J. Touchstone, John Wiley and Sons, Inc., New York, 1973, pp. 253-291. (See 211).
18. Shopsin B, Gershon S. Pharmacology - toxicology of the lithium ion. In: Lithium: Its Role in Psychiatric Research and Treatment, edited by S. Gershon and B. Shopsin, Plenum Press, New York, 1973, pp. 107-146.
19. Angrist B, Shopsin B, Wilk S, Gershon S. The effects of amphetamine on behavior and monoamine metabolites in urine and cerebrospinal fluid. In: Drug Addition, Vol. 4, New Aspects of Analytical and Clinical Toxicology, edited by J.M. Singh and H. Lal, Stratton Intercontinental Medical Books, New York, 1974, pp. 39-44.
20. Burdock EI, Gershon S. Methodology for evaluating antipsychotic agents. In: Principle and Techniques of Human Research Therapeutics (Series) Vol. 8, Psychopharmacological Agents, edited by E.G. McMahon, Futura Publ. Co., New York, 1974, pp. 73-104.
21. Chan TL, Gershon S. Quantitation of chlorpromazine and its metabolites in human plasma urine by thin-layer chromatography. In: Phenothiazines and Structurally Related Drugs, edited by I.S. Forrest, C.J. Carr and E. Usdin, Raven Press, New York, 1974, pp. 323-333. (See also 205).
22. Ho AK, Tsai CS, Gershon S. Adrenergic-cholinergic interaction in the central nervous system and amphetamine-induced behavior. In: Drug Addition, Vol. 3: Neurobiology and Influences on Behavior, edited by J. Singh and H. Lal, Stratton, New York, 1974, pp. 259-69.
23. Gershon S. Lithium. In: American Handbook of Psychiatry, Vol. V., ed. by D. Freedman and J.E. Drug. Basic Books, New York, 1974, pp. 490-513.
24. Angrist B, Sathananthan G, Wilk S, Gershon S. A mphetamine psychosis: Behavioral and biochemical aspects. In: Catecholamines and Schizophrenia, ed. by S.W. Matthysse and S.S. Kety, Pergamon Press, Oxford, 1975, pp. 13-23.
25. Shopsin B, Janowski D, Davis J, Gershon S. Rebound phenomena in manic patients following physostigmine: Towards an understanding of the aminergic mechanisms underlying affective disorders. In: Neurotransmitter Balances Regulating Behavior, ed. by E.F. Domino and J.M. Davis, Edwards, Ann Arbor, 1975, pp. 149-58.
26. Kelwala S, Gershon S. The treatment of manic depressive states. In: Manual of Psychiatric Therapeutics, edited by R.I. Shader, Little Brown Publishers, Boston, 1975, pp. 101-114.
27. Sathananthan GL, Gershon S. Cerebral vasodilators: A review. In: Agging, Vol. 2: Genesis and Treatment of Psychologic Disorders in the Edlerly, edited by S. Gershon and A. Raskin, Raven Press, New York, 1975, pp. 155-168.
28. Schooler NR, Sakalis G, Chan TL, Gershon S, Goldberg SC, Collins P. Chlorpromazine metabolism and clinical response in acute schizophrenia: A preliminary report. In: Pharmacokinetics of Psychoactive Drugs, ed. by L.A. Gottschalk and Merlis. Spectrum Publications, New York, 1976, pp. 199-219.
29. Shopsin B, Gershon S, Selzer G. Neuropsychopharmacology of mania. In: Drug Treatment of Mental Disorders, edited by L. Simpson, Raven Press, New York, 1976, pp. 12.
30. Gershon S. Lithium. In: Psychotherapeutic Drugs, Part II - Applications, ed. by E. Usdin and I.S. Forrest. In Volume II of a series called Psychopharmacology, edited by E. Usdin, 1977, pp. 1377-1411, IX Antimanics, 1. Lithium.

31. Angrist B, Sathananthan G, Shopsin B, Gershon S. The comparative psychotogenic effects of L-dopa and ET-495. In: Cocaine and Other Stimulants, ed. by E.H. Ellingwood, Jr. and M.M. Kilbey, Plenum Press, New York, 1977, pp. 689-704.
32. Gershon S, Angrist B, Shopsin B. Pharmacological agents as tools in psychiatric research. In: The Impact of Biology on Modern Psychiatry, ed. by E.S. Gershon, et al, Plenum Press, New York, 1977, pp. 65-93.
33. Sanghvi IS, Gershon S. Animal test models for prediction of clinical antidepressant activity. In: Animal Models in Psychiatry and Neurology, ed. by I. Hanin and E. Usdin, Pergamon Press, Oxford, 1977, pp. 151-69.
34. Sakalis G, Sudilovsky A, Traficante LJ, Sathananthan GL, Rotrosen J, Van Vunakis H, Gershon S. Clinical response and plasma levels of fluphenazine: Pharmacokinetic and methodological considerations. In: Ayd Medical Communications -Depot Fluphenazines: Twelve Years of Experience, (ayddepo 20988) edited by F.J. Ayd, Jr., pp. 72-87, 1978.
35. Gershon S. The pharmacotherapy of manic depressive disorders. In: Principles and Techniques of Human Research and Therapeutics; a series of monographs edited by F. Gilberg McMahon, M.D., Vol. XII: Contemporary Standards for the Pharmacotherapy of Mental Disorders, edited by J. Levine, Futura Publishing Co., Inc., New York, 1978, VI: 117-183.
36. Shopsin B, Gershon S. Lithium: Clinical Considerations. In: Handbook of Psychopharmacology, Vol. 14 edited by L.L. Iverson, S.D. Iverson and S.H. Snyder, Plenum Publishing Corp., New York, 1978, pp. 275-325.
37. Gerbino A, Oleshansky M, Gershon S. Clinical use and mode of action of lithium. In: Psychopharmacology: A Generation of Progress, edited by M.A. Lipton, A. DiMascio and K.F. Killman, Raven Press, New York, 1978, pp. 1261-1275.
38. Annito W, Gershon S. Antimanic agents: Lithium and mania: Plasma levels and response. In: Plasma Levels Measurement of Psychotropic Drugs and Clinical Response, edited by G. Burrows, M. Dekker, Inc., New York, 1978.
39. Reisberg B, Gershon S. Toxicology and side effects of lithium therapy. In: Lithium/Controversies and Unresolved Issues, edited by T.B. Cooper, S. Gershon, N.S. Kline and M. Schou. Side Effects 1979; VII: 449-478, Excerpta Medica, Amsterdam-Oxford-Princeton. Proceedings of the International Lithium Conference, New York, June 5-9, 1978.
40. Reisberg B, Ferris SH, Gershon S. Psychopharmacologic aspects of cognitive research in the elderly: Some current perspectives. In: Interdisciplinary Topics in Gerontology, Volume 15, CNS Aging and Its Neuropharmacology: Experimental and Clinical Aspects, edited by W. Meier-Ruge and H. van Hahn, S. Karger Basel, 1979, pp. 132-152.
41. Ferris SH, Sathananthan G, Gershon S, Crook T. Neurotransmitter precursors and neuropeptides in senile dementia. In: Recent Advances in Gerontology, Proceedings of the XI International Congress of Gerontology, Tokyo, Aug. 20-25, 1978, Excerpta Medica, Amsterdam-Oxford-Princeton, 1979, pp. 228-229.
42. Georgotas A, Gershon S. Lithium in manic-depressive illness: Some highlights and current controversies. In: Lithium Controversies and Unresolved Issues, ed. by S. Gershon, M. Schou, N. Klein and T. Cooper, Excerpta Medica, Amsterdam, 1979, pp. 57-84.
43. Rotrosen J, Gershon S. Growth hormone, prostaglandins, and receptor-sensitivity in schizophrenia. In: Biological Psychiatry Today, edited by J. Obiols, C. Ballus, E. Gonzalez-Monclus and J. Pryol, Elsevier North Holland Biomedical Press, 1979, pp. 123-127.

44. Gerbino L, Gershon S. Psychopharmacology - Antipsychotic Drugs. In: PKSAP-IV Syllabus, American Psychiatric Association, Washington, DC, 1979, pp. 150-169.
45. Angrist B, Gershon S. The effect of lithium pretreatment on cardiovascular and behavioral responses to amphetamine. International Catecholamine Symposium, Pacific Grove, California, 4th. In: Catecholamines: Basic and Clinical Frontiers, edited by E. Usdin, I. Kopin and J. Barchas, Pergamon Press, New York, 1979.
46. Gershon S, Newton R. A multicentered controlled evaluation of trazadone in endogenous depression. Reprinted from Trazodone: a new broad-spectrum antidepressant, ed. by S. Gershon, K. Rickels and B. Silvestrini, Excerpta Medica, Amsterdam, 1980, pp. 42-53.
47. Mann J, Gershon S. Absolute and relative contraindications to lithium therapy. In: Handbook of Lithium Therapy, edited by F.N. Johnson, MTP Press, England, 1980, pp. 265-278.
48. Annitto W, Prien R, Gershon S. The lithium ion: Is it specific for mania? In: Mania an Evolving Concept, edited by R.H. Belmaker and H.M. vanPragg. SP Medical and Scientific Books, New York, 1980, pp. 127-141.
49. Gershon S. Part I: Disciplines relevant to biological psychiatry. In: Handbook of Biological Psychiatry, ed. by H.M. vanPragg, M.H. Lader, O. Rafaelson and E.J. Sachar, Marcell Dekker, Inc., New York, 1980.
50. Ferris SH, Reisberg B, Gershon S. Neuropeptide modulation on cognition and memory in humans. Ch. 15, Sec. 4. In: Aging in the 1980's: Selected Issues in the Psychology of Aging, ed. by L.W. Poon, American Psychological Association, Washington, DC, 1980, pp. 212-220.
51. Reisberg B, Ferris SH, Gershon S. Pharmacotherapy of senile dementia. Proc. Annu. Meeting American Psychopathol. Association, 1980; 69: 233-64. In: Psychopathology in the Aged, edited by J. Cole and J. Barrett, Raven Press, New York, 1980, pp. 233-264.
52. Annitto W, Gershon S. Antimanic agents. Lithium & Mania: Plasma levels & response. In: Psychotropic Drugs - Plasma Concentration and Clinical Response, ed. by G.D. Burrows and T.R. Norman, Marcel Dekker, Inc., New York, 1980, pp. 231-241.
53. Prien RF, Gershon S. Lithium therapy in the elderly. In: Physicians' Handbook on Psychotherapeutic Drug Use in the Aged, ed. by T. Crook and G. Cohen, Mark Powley Assoc., Inc., 1981.
54. Gershon S. Evaluation of trazodone, a unique antidepressant, in the treatment of endogenous depression: Results of a multi-centre double-blind study. In: New Directions in Antidepressant Therapy: An International Review of the Triazolopyridine Derivatives, The Royal Society of Medicine, New York, 1981, Series 46, pp. 48-59.
55. Domino E, Minor L, Duff I, Tait S, Gershon S. Effects of oral lecithin on both blood choline levels and memory tests in geriatric volunteers. In: Memory Disorders of Aging: Strategies for New Treatments, edited by Richard Wurtman, Raven Press, New York, 1981.
56. Goodnick P, Gershon S. Treatment of cognitive disorders. In: Geriatric Psychopharmacology, edited by C. Salzman, McGraw Hill Publishing Co., 1981.
57. Pomara N, Reisberg B, Ferris SH, Gershon S. Drug treatment of cognitive decline. In: Behavioral Assessment and Psychopharmacology - Advances in Neurogerontology, edited by F.J. Pirozzolo and G.J. Maletta, Praeger Press, New York, 1981, pp. 107-143.

58. Kinon BJ, Gershon S. Controversial issues in psychiatric assessment. In: The Behavior of Psychiatric Patients, ed. by E.I. Burdock, A. Sudilovsky and S. Gershon, Marcel Dekker, New York, 1982, pp. 87-101.
59. Domino EF, Minor L, Duff IF, Tait S, Gershon S. Effects of oral lecithin on blood choline levels and memory tests in geriatric volunteers. In: Alzheimer's Disease: A Review of Progress (Aging, Volume 19), edited by S. Corkin, et al., Raven Press, New York, 1982, pp. 391-395.
60. Pomara N, Goodnick PJ, Brinkman SD, Domino E, Gershon S. A dose-response study of lecithin in the treatment of Alzheimer's disease. In: Alzheimer's Disease: A Report of Progress, (Aging, Volume 19), edited by S. Corkin, et al., Raven Press, New York, 1982, pp. 379-383.
61. Gershon S, Georgotas A, Newton R, Bush D. Clinical evaluation of two new antidepressants. In: Typical and Atypical Antidepressants: Clinical Practice, edited by E. Costa, G. Racagni, Raven Press, New York, 1982, pp. 57-68.
62. Ferris SH, Reisberg B, Crook T, Friedman E, Schneck MK, Mis P, Sherman KA, Corwin J, Gershon S, Bartus RT. Pharmacologic treatment of senile dementia: Choline, L-Dopa, Piracetam, and Choline plus Piracetam. In: Alzheimer's Disease: A Report of Progress, (Aging Volume 19), edited by S. Corkin, et al., Raven Press, New York, 1982, pp. 475-81.
63. Gershon S. Dopamine receptors and their behavioral correlates. Special Symposium D., Collegium Internationale Neuro-Psychopharmacologicum, 13th C.I.N.P. Congress, June 22, 1982, Jerusalem, Israel. In: Pharmacology, Biochemistry & Behavior, ed. by M.J. Wayner ANKHO International Inc., New York, 1982, 17:1.
64. Pohl R, Gershon S. Newer antidepressants - clinical aspects. In: Drugs and Psychiatry, Vol. I, Antidepressants, ed. by Burrows, Norman and Davies, Elsevier/North Holland and Biomedical Press, New York, 1983, pp. 187-206.
65. Goodnick P, Gershon S. Chemotherapy of cognitive disorders. In: Aging of the Brain, edited by D. Samuel, et al., Raven Press, New York, 1983, pp. 349-361.
66. Pohl R, Gershon S. Affective Disorders, method of. In: Current Therapy 1983: Latest Approved Methods of Treatment for The Practicing Physician, edited by H.F. Conn, W.B. Saunders, Co., 1983, pp. 904-908.
67. Pomara N, Brinkman S, Gershon S. Pharmacologic treatment of Alzheimer's disease: Future directions. In: Alzheimer's Disease, ed. by B. Reisberg, The Free Press, Div. of MacMillan, Inc., New York, 1983, pp. 387-395.
68. Gershon S. Trazodone Hydrochloride. In: June 1983 Formulary, Antidepressants 28:16.04. American Society of Hospital Pharmacists, Inc.
69. Ortiz A, Dabbagh M, Gershon S. Lithium: Clinical use, toxicology and mode of action. In: Clinical Psychopharmacology, Second Edition, edited by J.G. Bernstein, John Wright-PSG, Inc., 1984, pp. 111-144.
70. Pohl R, Gershon S. Affective disorders, method of. In: Conn's Current Therapy, edited by R.E. Rakel, W. B. Saunders Co., 1984, pp. 900-904.
71. Goodnick P, Gershon S, Salzman C. Dementia and memory loss in the elderly. In: Clinical Geriatric Psychopharmacology, edited by Carl Salzman. McGraw-Hill Book Co., 1984, pp. 171-198.

72. Goodnick P, Gershon S. Chemotherapy of cognitive disorders in geriatric subjects. Aging of the Central Nervous System and Psychopathology Acta Neurologica - Facolta di Medicina, Universita di Napoli, 1984, pp.69-96.
73. Meyendorff E, Lerer B, Moore N, Bow J, Gershon S. Methylphenidate infusion in euthymic bipolars: Effect of carbamazepine pretreatment. In: Psychiatry Research, Elsevier, 1985, 14.
74. Goodnick PJ, Gershon S. Lithium. In: Handbook of Neurochemistry, Volume 9, edited by A. Lajtha, New York, Plenum Publishing Co., 1985, pp. 103-149.
75. Dabbagh M, Stanley M, Gershon S. New antipsychotic agents: Clinical studies. In: Antipsychotics, Volume 3, Drugs in Psychiatry Series, edited by G.D. Burrows, T. Norman and B. Davies, Elsevier Science Publishers B.V. (Biomedical Div.), Amsterdam, 1985, pp. 147-161.
76. Jain, A.K., Kelwala, S., Gershon, S. Alternative to lithium: How great is the need and how viable are the candidates? In: Biological Psychiatry 1985, (Proceedings of the IV World Congress of Biological Psychiatry held September 8-13, 1985, Philadelphia, PA), edited by C. Shagass, R.C. Josiassen, W.H. Bridger, K.J. Weiss, D. Stoff, and M. Simpson. Elsevier Science Publ. Co., Inc., 1986, pp. 720-722.
77. Pohl, R., Rainey, J.M., Gershon, S. Compounds affecting the noradrenergic and serotonergic systems: Clinical studies. In: Biological Psychiatry 1985, (Proceedings of the IVth World Congress of Biological Psychiatry held September 8-13, 1985, Philadelphia, PA), edited by C. Shagass, R.C. Josiassen, W.H. Bridger, K.J. Weiss, D. Stoff and G.M. Simpson, Elsevier Science Publ. Co., Inc., 1986, pp. 598-600.
78. Rainey JM, Pohl R, Ortiz A, Yeragani V, Frohman CE, Gershon S. Isoproterenol anxiety states. In: Biological Psychiatry 1985, (Proceedings of the IVth World Congress of Biological Psychiatry held from September 8-13, 1985, Philadelphia, PA), edited by C. Shagass, R.C. Josiassen, W.H. Bridger, K.J. Weiss, D. Stoff and G.M. Simpson, Elsevier Science Publ. Co., 1986, pp.648-650.
79. Moore, N., Lerer, B., Meyendorff, E., Gershon, S. Carbamazepine in the acute treatment of mania. In: Biological Psychiatry 1985, (Proceedings of the IVth World Congress of Biological Psychiatry held September 8-13, 1985, Philadelphia, PA), edited by C. Shagass, R.C. Josiassen, W.H. Bridger, K.J. Weiss, D. Stoff and G.M. Simpson, Elsevier Science Publ. Co., Inc., 1986, pp. 726-728.
80. Gershon, S. Chronic pain: hypothesized mechanism and rationale for treatment. In: Biological Psychiatry 1985, (Proceedings of the IVth World Congress of Biological Psychiatry held September 8-13, 1985, Philadelphia, PA), edited by C. Shagass, R.C. Josiassen, W.H. Bridger, K.J. Weiss, D. Stoff, G.M. Simpson, Elsevier Science Publ. Co., 1986, pp. 747-749.
81. Altman H, Normile H, Gershon S. Non-cholinergic pharmacology in human cognitive disorders. In: Cognitive Neurochemistry S.D. Iversen, H. Goodman and S.M. Stahl. Oxford University Press, 1987, pp. 346-371.
82. Moore, N.C., Gershon, S. Antipsychotic drugs in mania. In: Antimanic, anticonvulsants and other drugs in psychiatry, edited by G.D. Burrows, T. Norman and B. Davies. Elsevier Science Publ., B.V. (Biomedical division), 1987, 3:35-47.
83. Normile HJ, Altman HJ, Gershon S. Issues regarding possible therapies using cognitive enhancers. In: Attention Deficit Disorder: Clinical and Basic Research, edited by T. Sagvolden and T. Archer, Lawrence Erlbaum Associates Inc., New York, 1989, pp. 287-315.
84. Goldman H, Berman R, Gershon S, Murphy S, Altman H. Correlation of behavioral and cerebrovascular functions in the aging rat. Neurobiology of Aging, Vol. 8, pp. 409-416, 1987.

85. Pohl R, Gershon S. The use of new antidepressants for tricyclic-resistant patients. In: Treating Resistant Depression, edited by J. Zohar and R.H. Belmaker, PMA Publ Corp., New York, 1987, pp. 237-255.
86. Oxenkrug GF, Gershon S. Cognitive function & brain-adrenal axis activity in aging, depression and dementia. In: Alzheimers Disease, edited by H. J. Altman, Plenum Publishing Corporation, 1987, pp.59-66.
87. Thornton JE, Gershon S. The History of THA. In: Current Research in Alzheimer Therapy, edited by E. Giaconini and R. Becker, Taylor & Francis, New York, 1988, pp. 267-278.
88. Zimmer B, Gershon S. The Ideal late life anxiolytic. In: Anxiety in the Elderly, edited by Carl Salzman and Barry Lebowitz. Springer Verlag, New York, 1990. pp. 277-303.
89. Altman HJ, Gershon S, Normile HJ. Dementia: The role of behavioral models. In: Behavioral Models in Psychopharmacology: Theoretical, Industrial and Clinical Perspectives, ed. by P. Willner. Oxford University Press, 1990, pp. 437-450.
90. Wright B, Rosenberg D, Gershon S. New strategies for the pharmacologic therapy of adult onset cognitive disorders. In: Diagnosis and Treatment of Adult Onset Cognitive Disorders, ed. by T. Crook and S. Gershon. Old Saybrook, CT: Psymark Communications, Inc., 1991. pp. 182-221.
91. Gershon S, Bruinvels J. (Eds.) Psychopathology: New Findings with Anxiolytic Drugs. Proceedings of a satellite conference held during the XVIth Collegium International Neuro-Psychopharmacologicum (C.I.N.P. Congress). Volume 22, Supplement 1, 1989.
92. Gershon S, Ferris S, Kennedy J, Kurtz N, Overall J, Pollock B, Reisberg B, Whitehouse P. Methods for the evaluation of pharmacologic agents in the treatment of cognitive and other deficits in dementia. In: Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines, ed. by R.F. Prien and D.S. Robinson. New York: Raven Press. pp. 467-499, 1994.
93. Houlihan D, Gershon S. Role of monoamine oxidase inhibitors in psychiatry. In: Monoamine Oxidase Inhibitors in Neurological Diseases, edited by A. Lieberman, C.W. Olanow, M.B.H. Youdim, K. Tipton. New York: Marcel Dekker, Inc. Chapter 15, pp. 295-351, 1994.
94. Soares J, Gershon S. Nootropics and agents for treating Alzheimer's disease. In: Handbook of Pharmacology of Aging, 2nd Edition, ed. by J. Roberts & D.L. Snyder. Boca Raton, FL: CRC Press, Inc. Chapter 12, pp. 197-225, 1996.
95. Mallinger A, Gershon S. Summary/Comment. In: Mania: Clinical and research perspectives. Edited by P.J. Goodnick. Washington, DC: American Psychiatric Press, Inc. Chapter 18, pp. 383-396, 1998.
96. Soares JC, Gershon S. Prospects for the Development of New Treatment with a Rapid Onset of Action in Affective Disorders. In: Disease Management Review - Depression. Auckland: Adis International, 1998:I:71-76.
97. Soares JC, Gershon S. The psychopharmacological specificity of the lithium ion - origins and trajectory. In: Lithium: 50 years of psychopharmacology new perspectives in biomedical and clinical research, edited by N.J. Birch, V.S. Gallicchio, and R.W. Becker. Weidner Publishing Group, Cheshire, CT, 1999. pp. 9-21.
98. Antelman SM, Levine J, Gershon S, Edwards DJ, Caggiula AR. Cyclic and Oscillatory Behaviors in Biological Systems – A Relevant Model for Bipolar Disorder. In: Bipolar Disorders, Basic Mechanisms and Therapeutic Implications. Ed. by Soares JC, Gershon S. New York: Marcel Dekker, Inc. 2000. pp. 49-58,

99. Gershon S, Levine J. Prophylaxis in Psychiatry. In: International encyclopedia of the social & behavioral sciences, ed. by Neil J. Smelser, Paul B. Baltes. 1st ed. Amsterdam; New York: Elsevier, 2001.
100. Levine J, Soares JC, Chengappa KNR, Gershon S. Lithium Treatment of Bipolar Disorder Patients. In: Bipolar Disorder: A Clinician's Guide to Biological Treatments. ed. by Yatham LN, Kusumakar V, Kutcher S. Brunner-Routledge Inc. 2002. pp. 139-166.
101. Gershon S, Levine J. Is Phenomenological Dissection for Bipolar Disorders Spectrum Possible? In: Bipolar Disorder. Ed. by Maj M, Akiskal, HS, Lopez-Ibor JJ & Sartorius, N. Wiley. 2002. pp. 60-62.
102. Daversa C, Gershon S. The Lithium Story: A journey from obscurity to popular use in North America. In: Baur M, Grof P, Muller-Oerlinghausen B, eds. *Lithium in Neuropsychiatry: The Comprehensive Guide*. Taylor & Francis Book Ltd., London, UK. 2006: 17-24.

Samuel Gershon
Additional bibliography 2008–2014

- Martinez-Arán A, Vieta E, Chengappa KN, Gershon S, Mullen J, Paulsson B. Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. *Bipolar Disord* 2008; 10(5): 566–579.
- Gershon S, Chengappa KN, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. *Bipolar Disord* 2009; 11 (Suppl. 2): 34–44.
- Malhi GS, Gershon S. Ion men and their mettle. *Aust N Z J Psychiatry* 2009; 43(12): 1091–1095.
- Gershon S, Chengappa KN. Lithium: the long road. *Bipolar Disord* 2010; 12(7): 667–668.
- Malhi GS, Chengappa KN, Gershon S, Goldberg JF. Hypomania: hype or mania? *Bipolar Disord* 2010; 12(8): 758–763.
- Malhi GS, Tanious M, Gershon S. The lithiumeter: a measured approach. *Bipolar Disord* 2011; 13(3): 219–226.
- Malhi GS, Chengappa KN, Gershon S, Ghaemi SN. Atypical mood stabilizers: a new role for neuroleptics? *Bipolar Disord* 2011; 13(7-8): 583-586.
- Gershon S, Chengappa KN, Malhi GS. A new 'face' for bipolar disorders? *Bipolar Disord* 2012; 14(7): 681–683.
- Malhi GS, Gershon S. A DeCade of science. *Aust N Z J Psychiatry* 2014; 48: 7–9.
- Malhi GS, Rosenberg DR, Gershon, S. Staging a protest! *Bipolar Disord* 2014; doi 10.1111/bdi.12254.